Note: Descriptions are shown in the official language in which they were submitted.
81565053
- 1 -
THIAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER
BACKGROUND OF THE INVENTION
The invention had the object of finding novel compounds having valuable
properties, in particular those which can be used for the preparation of
medicaments.
One of the principal mechanisms by which cellular regulation is effected is
through the transduction of extracellular signals across the membrane that
in turn modulate biochemical pathways within the cell. Protein phosphoryl-
ation represents one course by which intracellular signals are propagated
from molecule to molecule resulting finally in a cellular response. These
signal transduction cascades are highly regulated and often overlap, as is
evident from the existence of many protein kinases as well as phosphata-
ses. Phosphorylation of proteins occurs predominantly at serine, threonine
or tyrosine residues, and protein kinases have therefore been classified by
their specificity of phosphorylation site, i.e. serine/threonine kinases and
tyrosine kinases. Since phosphorylation is such a ubiquitous process
within cells and since cellular phenotypes are largely influenced by the
activity of these pathways, it is currently believed that a number of disease
states and/or diseases are attributable to either aberrant activation or,
functional mutations in the molecular components of kinase cascades.
Consequently, considerable attention has been devoted to the characteri-
sation of these proteins and compounds that are able to modulate their
activity (for a review see: Weinstein-Oppenheimer et al. Pharma. &.
Therap., 2000, 88, 229-279).
The present invention relates to compounds and to the use of compoUnds in
which the inhibition, regulation and/or modulation of signal transduction by
protein kinases, in particular tyrosine kinases and/or serine/threonine
kinases,
plays a role, furthermore to pharmaceutical compositions which comprise
=
CA 2784067 2017-08-03
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 2 -
these compounds, and to the use of the compounds for the treatment of
kinase-induced diseases.
In particular, the present invention relates to compounds and to the use of
compounds in which the inhibition, regulation and/or modulation of signal
transduction by kinases plays a role, in particular the protein kinases NUAK1,
also known as ARK5, MAPK (MAP2K1, MAP4K2, MAP3K11), MARK3,
ROCK2, also known as Rho kinase 2, CHEK1, also known as CHK1, CDK2,
PKN2, KDR, also known as VEGFR, HIPK1 and AURORA.
MAPxKy (mitogen-activated protein (MAP) kinase
The protein encoded by this gene is a member of the dual-specific protein
kinase family which functions as a mitogen-activated protein (MAP) kinase.
MAP kinases, also described as extracellular signal-regulated kinases
(ERKs), function as integration point for various biochemical signals.
MAP2K1 is located in front of other MAP kinases in the signal cascade and
stimulates the enzymatic activity thereof as a function of many extra- and
intracellular signals. As an essential component of the MAP kinase signal
transduction pathway, MAP2K1 is involved in many cellular processes,
such as proliferation, differentiation, transcription regulation and cell
devel-
opment.
Similar considerations apply to other MAPKs.
The compound RO-4927350, a thiazole derivative, has been described by K.
Kolinsky et al. as MEK inhibitor for the specific inhibition of the MAPK
signal
transduction cascade in Cancer Res. 2009; 69: 1924 ff., where the compound
has an antitumour activity in vivo.
T. Kato et al. in Neoplasia 2001; 3 (1): 4-9, describe MARK3 (homologous to
MARKL1) as potential target for the treatment of hepatocellular carcinogene-
sis.
CHEK1
Studies confirm that CHEK1 inhibition increases the cytotoxicity of DNA-
damaging agents (Xiao Z, Chen Z, Gunasekera AH, et al. Chk1 mediates
CA 02784067 2012-06-12
WO 2011/0727'79
PCT/EP2010/006822
- 3 -
S and G2 arrests through Cdc25A degradation in response to DNA-dam-
aging agents, J. Biol. Chem. 2003; 278: 21767 ¨ 73;
Xiao D, Herman-Antosiewicz A, Antosiewicz J, et al. Diallyl trisulfide-
induced G(2)-M phase cell cycle arrest in human prostate cancer cells is
caused by reactive oxygen species-dependent destruction and hyperphos-
phorylation of Cdc 25 C, Oncogene 2005; 24: 6256 ¨ 68;
Zhao B, Bower MJ, McDevitt PJ, et al. Structural basis for Chk1 inhibition
by UCN-01, J. Biol. Chem. 2002; 277: 46609¨ 15;
Maude SL, Enders GH. Cdk inhibition in human cells compromises chk1
function and activates a DNA damage response. Cancer Res. 2005; 65:
780 ¨ 6.)
and the expression of CHEK1 is part of the defence mechanism of the cell
for avoiding the toxicity of DNA damage.
ROCK2
ROCK2 is a serine/threonine kinase which is activated by association with
RhoGTP, which results in phosphorylation of a multiplicity of substrates
and ultimately results in stabilisation of filamentous actin and an increase
in the activity of myosine ATPase. This in turn causes the formation of
contractile actin-myosine units (stress fibres) and integrin-containing focal
adhesions. Through the modulation of actin-myosine contractility, ROCK2
has a significant influence on the regulation of cell morphology, cell mobil-
ity and cell adhesion. C. Chak-Lui Wong et al. in Hepatology 2009; 49 (5):
1583 ¨ 94, describe that the inhibition of Rho kinases 1 and 2 (ROCK1 and
ROCK2) can be utilised for the treatment of cancer diseases. Thus,
ROCK2 plays a significant role in the growth of hepatocellular carcinomas.
X.Q. Wang et al. in Radiation Res. 2007; 168 (6): 706 - 15, describe the
checkpoint kinase CHK1 as potential target for the treatment of cancer.
NUAK1
The Nuak1 gene encodes for the "NUAK family SNF1-like kinase 1".
NUAK1 interacts with USPX9 and ubiquitin C.
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 4 -
The role of NUAK1 (ARK5) as growth or nutrition factor of tumour cells has
been described by A. Suzuki et al. in J. Biol. Chem. 2003; 278 (1): 48 - 53,
and in Oncogene 2003; 22: 6177 - 82.
The inhibition of NUAK1 (ARK5) thus represents a potential possibility for
combating cancer
CDK2
The deactivation of CDK2 prevents the phosphorylation of the protein RB1.
The cell is thus unable to leave the G1 phase of the cell cycle, which
=
results in stopping of all cell division.
J.K.Buolamwini in Current Pharmaceutical Design 2009; 6, (4): 379 - 92,
describes the therapeutic potential of CDK (cyclin dependent kinase)
inhibitors in the combating of cancer.
A. Schmidt et al. in EMBO J. 2007; 26: 1624 - 36, describe PRK2/PKN2 as
potential target for the treatment of tumour diseases.
N. Ferrara in Endocrine Rev. 2004; 25 (4): 581 - 611, describes the use VEGF
inhibitors for combating cancer.
VEGF and KDR represent a ligand-receptor pair which plays an essential role
in the proliferation of vascular endothelial cells and in the formation and
sprouting of blood vessels, which are known as vasculogenesis or angiogene-
sis.
Angiogenesis is characterised by above-average activity of vascular endo-
thelial growth factor (VEGF). VEGF actually consists of a family of ligands
(K(agsburn and D'Amore, Cytokine & Growth Factor Rev. 1996; 7: 259 - 70,).
VEGF binds the high-affinity membrane-spanning tyrosine kinase receptor
KDR and the related fms tyrosine kinase-1, also known as Flt-1 or vascular
endothelial cell growth factor receptor 1 (VEGFR-1). Cell culture and gene
knockout experiments indicate that each receptor contributes to different
aspects of angiogenesis. KDR mediates the mitogenic function of VEGF,
whereas Flt-1 appears to modulate non-mitogenic functions, such as those
associated with cellular adhesion. Inhibition of KDR thus modulates the level
of mitogenic VEGF activity. In fact, it has been shown that tumour growth is
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 5 -
influenced by the antiangiogenic action of VEGF receptor antagonists (Kim et
al., Nature 1993; 362: 841 -4).
Three PTK (protein tyrosine kinase) receptors for VEGFR have been identi-
fied: VEGFR-1 (Flt-1); VEGRF-2 (Flk-1 or KDR) and VEGFR-3 (Flt-4).
The fact that the inhibition of VEGFR (vascular endothelial growth factor
receptor 2 ¨ KDR) is of importance for tumour therapy has been shown by
means of the introduced medicaments sunitinib, sorafenib and vatalanib,
which also inhibit VEGFR.
HIPK1
HIPK1, a nuclear protein kinase which is present in increased concentrations
in breast cancer cells, serves to phosphorylate various transcription factors,
including p53.
It can be assumed that HIPK1 plays a role in cancer and tumorigenesis by
regulating p53 and/or the Mdm2 function.
Y. Aikawa et al. in EMBO J. 2006; 25: 3955 - 65, describe the homeodomain-
interacting protein kinases HIPK1, HIPK2 and HIPK3 as potential targets for
the treatment of tumour diseases.
R. Copeland et al. in FASEB J. 2008; 22: 1050 ff., describe HIPK1 as target
for the treatment of cancer diseases.
HIPK2 (homeodomain interacting protein kinase)
The significantly increased expression of HIPK2 in cervical cancer seems
to correlate with the progression of the disease (Eva Krieghoff-
Henningjavascript:popReifal) & Thomas G Hofmann Future Oncology
2008; 4 (6): 751 ¨ 54).
The role of aurora kinase inhibitors in the treatment of tumours are described
by a number of authors;
D.S. Boss et al., The Oncologist 2009; 14: 780 - 93;
S. Lapenna et al., Nature Rev. Drug Discov. 2009; 8: 547 - 66;
L. Garuti et al., Cur. Med. Chem. 2009; 16, 1949 - 63;
J. R. Pollard et al., J. Med. Chem. 2009; 52 (9): 2629 - 51;
CA 02784067 2012-06-12
W02011/072779 PCT/EP2010/006822
- 6 -
C.H.A. Cheung et al., Expert Opin. lnvestig. Drugs 2009; 18 (4): 379 - 98.
The present invention therefore relates to the use of the compounds of the
formula I for the treatment of diseases or conditions in which inhibition of
the
activity of protein kinases, in particular the protein kinases NUAK1, also
known
as ARK5, MAPK (MAP2K1, MAP4K2, MAP3K11), MARK3, ROCK2, also
known as Rho kinase 2, CHEK1, also known as CHK1, CDK2, PKN2, KDR,
also known as VEGFR, HIPK1 and AURORA, is advantageous.
The synthesis of small compounds which specifically inhibit, regulate
and/or modulate signal transduction by tyrosine kinases and/or serine/
threonine kinases, in particular the above-mentioned protein kinases, is
therefore desirable and an aim of the present invention.
It has been found that the compounds according to the invention and salts
thereof have very valuable pharmacological properties while being well tol-
erated.
The present invention specifically relates to compounds of the formula I
which inhibit, regulate and/or modulate signal transduction by protein
kinases, to compositions which comprise these compounds, and to proc-
esses for the use thereof for the treatment of kinase-induced diseases and
complaints, such as angiogenesis, cancer, tumour formation, growth and
propagation, arteriosclerosis, ocular diseases, such as age-induced
macular degeneration, choroidal neovascularisation and diabetic retino-
pathy, inflammatory diseases, arthritis, thrombosis, fibrosis, glomerulo-
nephritis, neurodegeneration, psoriasis, restenosis, wound healing, trans-
plant rejection, metabolic diseases and diseases of the immune system,
also autoimmune diseases, cirrhosis, diabetes and diseases of the blood
vessels, also instability and permeability and the like in mammals.
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 7 -
Solid tumours, in particular fast-growing tumours, can be treated with
kinase inhibitors. These solid tumours include monocytic leukaemia, brain,
urogenital, lymphatic system, stomach, laryngeal and lung carcinoma, in-
cluding lung adenocarcinoma and small-cell lung carcinoma.
The compounds of the formula la and lb can furthermore be used to pro-
vide additive or synergistic effects in certain existing cancer chemothera-
pies, and/or can be used to restore the efficacy of certain existing cancer
chemotherapies and radiotherapies.
It can be shown that the compounds according to the invention have an
antiproliferative action in vivo in a xenotransplant tumour model. The com-
pounds according to the invention are administered to a patient having a
hyperproliferative disease, for example to inhibit tumour growth, to reduce
inflammation associated with a lymphoproliferative disease, to inhibit trans-
plant rejection or neurological damage due to tissue repair, etc. The pre-
sent compounds are suitable for prophylactic or therapeutic purposes. As
used herein, the term "treatment" is used to refer to both prevention of dis-
eases and treatment of pre-existing conditions. The prevention of prolif-
eration is achieved by administration of the compounds according to the
invention prior to the development of overt disease, for example to prevent
the growth of tumours, prevent metastatic growth, diminish restenosis as-
sociated with cardiovascular surgery, etc. Alternatively, the compounds are
used for the treatment of ongoing diseases by stabilising or improving the
clinical symptoms of the patient.
The host or patient can belong to any mammalian species, for example a
primate species, particularly humans; rodents, including mice, rats and
hamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are of
interest for experimental investigations, providing a model for treatment of
human disease.
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 8 -
The susceptibility of a particular cell to treatment with the compounds
according to the invention can be determined by in vitro tests. Typically, a
culture of the cell is combined with a compound according to the invention
at various concentrations for a period of time which is sufficient to allow
the
active agents to induce cell death or to inhibit migration, usually between
about one hour and one week. In vitro testing can be carried out using cul-
tivated cells from a biopsy sample. The viable cells remaining after the
treatment are then counted.
The dose varies depending on the specific compound used, the specific
disease, the patient status, etc. A therapeutic dose is typically sufficient
considerably to reduce the undesired cell population in the target tissue
while the viability of the patient is maintained. The treatment is generally
continued until a considerable reduction has occurred, for example an at
least about 50% reduction in the cell burden, and may be continued until
essentially no more undesired cells are detected in the body.
For identification of a signal transduction pathway and for detection of
interactions between various signal transduction pathways, various scien-
tists have developed suitable models or model systems, for example cell
culture models (for example Khwaja et al., EMBO J. 1997; 16: 2783 - 93)
and models of transgenic animals (for example White et al., Oncogene
2001; 20: 7064 - 72). For the determination of certain stages in the signal
transduction cascade, interacting compounds can be utilised in order to
modulate the signal (for example Stephens et al., Biochemical J. 2000;
351: 95 - 105). The compounds according to the invention can also be
used as reagents for testing kinase-dependent signal transduction path-
ways in animals and/or cell culture models or in the clinical diseases men-
tioned in this application.
Measurement of the kinase activity is a technique which is well known to
the person skilled in the art. Generic test systems for the determination of
the kinase activity using substrates, for example histone (for example
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 9 -
Alessi et al., FEBS Lett. 1996; 399 (3): 333 - 8) or the basic myelin protein,
are described in the literature (for example Campos-Gonzalez, R. and
Glenney, Jr., J.R. J. Biol. Chem. 1992; 267: 14535).
For the identification of kinase inhibitors, various assay systems are avail-
able. In scintillation proximity assay (Sorg et al., J. Biomol. Screen. 2002;
7: 11 - 19) and flashplate assay, the radioactive phosphorylation of a pro-
tein or peptide as substrate with yATP is measured. In the presence of an
inhibitory compound, a decreased radioactive signal, or none at all, is
detectable. Furthermore, homogeneous time-resolved fluorescence reso-
nance energy transfer (HTR-FRET) and fluorescence polarisation (FP)
technologies are suitable as assay methods (Sills et al., J. Biomol. Screen.
2002; 7 (3): 191 - 214).
Other non-radioactive ELISA assay methods use specific phospho-anti-
bodies (phospho-ABS). The phospho-AB binds only the phosphorylated
substrate. This binding can be detected by chemiluminescence using a
second peroxidase-conjugated anti-sheep antibody (Ross et al. Biochem.
J. 2002, 366: 977 - 981).
There are many diseases associated with deregulation of cellular prolifera-
tion and cell death (apoptosis). The conditions of interest include, but are
not limited to, the following. The compounds according to the invention are
suitable for the treatment of various conditions where there is proliferation
and/or migration of smooth muscle cells and/or inflammatory cells into the
intimal layer of a vessel, resulting in restricted blood flow through that ves-
sel, for example in the case of neointimal occlusive lesions. Occlusive graft
vascular diseases of interest include atherosclerosis, coronary vascular
disease after grafting, vein graft stenosis, peri-anastomatic prosthetic
restenosis, restenosis after angioplasty or stent placement, and the like.
81565053
- 10 -
PRIOR ART
Other heterocyclic compounds have been described by various authors as
aurora kinase inhibitors for combating cancer:
L. Garuti et al., Curr. Med. Chem. 2009; 16: 1949 - 63;
J. R. Pollard et al., J. Med. Chem. 2009; 52 (9): 2629 - 51;
C.H.A. Cheung et al., Expert Opin. Investig. Drugs 2009; 18 (4): 379 - 98.
J.K.Buolamwini in Current Pharmaceutical Design 2000; 6, (4): 379 - 92,
= 10 describes other heterocyclic compounds, inter alia a
diaminothiazole
derivative, as CDK inhibitor.
Thiazolopyrazoles have been described as medicaments in WO
2005/095420.
The synthesis of pyrrolo[2,1-blthiazoles is described by A.V. Tverkhlebov
in Heterocycles 2007; 71: 761 - 98.
L. Grehn in Chemica Scripta 1978; 13: 78 - 95, describes processes for
the preparation of pyrrolothiazoles.
S. Athmani et al. in J. Chem. Soc. Perkin Trans. 1992; 973 - 77, describe
the synthesis of pyrrolo[2,3-d]thiazoles.
Another synthesis of pyrrolo[3,241thiazoles is described by A. Shafiee et
al. in J. Heterocyclic Chem. 1979; 16: 1563 - 66.
Other heterocyclic compounds are described as dyes by M.L.Dekhtyar in
Dyes and Pigments 2007; 74: 744 - 48.
Other pyrrolothiazoles are disclosed in keratin dye formulations in WO
2005/077324.
SUMMARY OF THE INVENTION
The invention relates to compounds of the formula la and lb
CA 2784067 2017-08-03
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 11 -
R7
I R3
N
1 R1 la lb
R2 S R5 s R6
Rt
in which
R1 denotes H, (CH2),-,Ar or (CH2)Flet,
R1' denotes H or A,
R2 denotes H, A, Hal, (CH2)nHet1, (CH2),-,Het3, -CF_C-Ar, (CH2),-,Ar2,
NHCONHAr, COA, COOH, COOA, COHetl, COAr2, CONH2,
CONHA, CONA2, SO2NH2, SO2NHA, S(0),,A, NHCOA, SO2NHA,
SO2NA2, SO2NHHet1, SO2NHAr2 or
R9
isRi
NH
{/ o
- -- ,
R3 denotes NHCOON or NH2,
R4 denotes (CH2)r,Ar, SiA3 or (CH2),-,Flet4,
R6 denotes H, Hal or (CH2)Het3,
R6 denotes H, -CEC-R4 or Hal,
R7 denotes H, A, Ar or Heti,
Ar denotes phenyl which is unsubstituted or mono-, di- or
trisubstituted
by Hal, A, OH, OA, CN, NO2, SO2A, COOH, COOA, NH2, NHA,
NA2, NHCH2Ar1, CHO, COA, CHO, CONH2, CONHA, CONA2, Het,
SO2NH2, SO2NHA, S(0),,A and/or NHCOA,
Het denotes a mono- or bicyclic aromatic heterocycle having 1 to 4
N, 0
and/or S atoms, which may be unsubstituted or mono-, di- or
trisubstituted by Hal, A, NH2, NHA, NA2, COOK COOA, CONH2,
GONNA, CONA2, CONHAr, CONHHet4, S(0)mA and/or NHCH2Ar1
,
Arl denotes phenyl which is unsubstituted or mono-, di- or
trisubstituted
by Hal, A, OH and/or OA,
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 12 -
Ar2 denotes phenyl which is monosubstituted by NHCONHHet4,
Heti denotes a mono- or bicyclic aromatic, unsaturated or saturated
heterocycle having 1 to 4 N, 0 and/or S atoms, which may be
unsubstituted or mono-, di- or trisubstituted by Hal, A, COOA, NH2,
NHR8 and/or (CH2)Het2,
R8 denotes H, A, Ar1 or Het4,
R9, R10 each, independently of one another, denote H or Hal,
R11 denotes H or A',
Het2 denotes a mono- or bicyclic aromatic heterocycle having 1 to 4 N,
and/or S atoms, which may be unsubstituted or mono-, di- or
trisubstituted by A, COOA and/or NH2,
Het3 denotes a mono- or bicyclic aromatic heterocycle having 1 to 4
N,
and/or S atoms, which may be unsubstituted or mono-, di- or
trisubstituted by NH2,
Hee denotes a mono- or bicyclic aromatic, unsaturated or saturated
heterocycle having 1 to 4 N, O and/or S atoms, which may be
unsubstituted or mono-, di- or trisubstituted by Hal, A, Ari, NH2,
NHCH2Ari and/or =0,
A denotes unbranched or branched alkyl haying 1-10 C atoms, in
which 1-7 H atoms may be replaced by F and/or in which one or
two non-adjacent CH and/or CH2 groups may be replaced by 0,
NH, NA', S, SO, SO2 and/or by CH=CH groups,
or
cyclic alkyl having 3-7 C atoms,
A' denotes unbranched or branched alkyl having 1-4 C atoms,
Hal denotes F, Cl, Br or I,
denotes 0, 1 or 2,
denotes 0, 1, 2, 3 or 4,
and pharmaceutically usable salts, tautomers and stereoisomers thereof,
including mixtures thereof in all ratios.
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 13 -
The compounds of the formula lb are synthetic precursors in the preparation
of compounds of the formula la, and, like the compounds of the formula la,
are potent kinase inhibitors.
Compounds of the formula la and lb are also taken to mean the hydrates
and solvates of these compounds, furthermore pharmaceutically usable
derivatives.
The invention also relates to the optically active forms (stereoisomers), the
enantiomers, the racemates, the diastereomers and the hydrates and sol-
vates of these compounds. The term solvates of the compounds is taken
to mean adductions of inert solvent molecules onto the compounds which
form owing to their mutual attractive force. solvates are, for example,
mono- or dihydrates or alkoxides.
Pharmaceutically usable derivatives are taken to mean, for example, the
salts of the compounds according to the invention and also so-called pro-
drug compounds.
Prodrug derivatives are taken to mean compounds of the formula la and lb
which have been modified by means of, for example, alkyl or acyl groups,
sugars or oligopeptides and which are rapidly cleaved in the organism to
form the effective compounds according to the invention.
These also include biodegradable polymer derivatives of the compounds
according to the invention, as described, for example, in Int. J. Pharm.
1995; 115: 61 -67.
The expression "effective amount" denotes the amount of a medicament or
of a pharmaceutical active ingredient which causes in a tissue, system,
animal or human a biological or medical response which is sought or de-
sired, for example, by a researcher or physician.
In addition, the expression "therapeutically effective amount" denotes an
amount which, compared with a corresponding subject who has not
received this amount, has the following consequence:
81565053
- 14 -
improved treatment, healing, prevention or elimination of a disease, syn-
drome, condition, complaint, disorder or side-effects or also the reduction
in the advance of a disease, complaint or disorder.
The term "therapeutically effective amount" also encompasses the
amounts which are effective for increasing normal physiological function.
The invention also relates to the use of mixtures of the compounds of the
formula la and lb, for example mixtures of two diastereomers, for example
in the ratio 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:100 or 1:1000.
These are particularly preferably mixtures of stereoisomeric compounds.
The invention relates to the compounds of the formula la and lb and salts
thereof and to a process for the preparation of compounds of the formula la
and lb and pharmaceutically usable salts, tautomers and stereoisomers
thereof, characterised in that
a) for the preparation of a compound of the formula la',
R7
,N
la'
R2 s R1
in which
R1 denotes Ar or Het,
R2 has the meanings described herein, apart from Hal,
R7 denotes tert-butyloxycarbonyl,
and Ar and Het have the meanings described herein,
a compound of the formula Ilc
N¨ R7
Ilc
R2
CA 2784067 2017-08-03
81565053
- 15 -
in which =
R2 has the meaning described herein, apart from Hal,
R7 denotes tert-butyloxycarbonyl,
is reacted with a compound of the formula IIIc
R1-CH=CH-CH2Br IIIc
in which R1 denotes Ar or Het,
and Ar and Het have the meanings described herein,
and the tert-butyloxycarbonyl group is subsequently or simultaneously
cleaved off,
or
b) for the preparation of a compound of the formula lb',
R3
lb'
R5 R6
in which
R3 denotes NH-000-tert-butyl,
R5 denotes H or (CH2)6Het3,
R6 denotes -CEC-R4
and
n, R4 and Het3 have the meanings described herein,
a compound of the formula Ild
CA 2784067 2017-08-03
81565053
- 16 -
N¨ R7
Ild
R5 S
in which
R7 denotes tert-butyloxycarbonyl,
R2 denotes H or (CH2)nHet3,
and Het3 has the meaning described herein,
is reacted with a compound of the formula Illd
H-CEC-R4 111d,
in which R4 has the meaning described herein,
or
c) for the preparation of a compound of the formula lb"
R3
lb"
R5 R6
in which
R3 denotes NH-000-tert-butyl,
R6 denotes Cl,
R6 denotes -C--.C-R4
and
R4 has the meaning described herein,
CA 2784067 2017-08-03
81565053
- 17 -
a compound of the formula lb",
R3
lb"
R5 s R6
in which
R3 denotes NH-000-tert-butyl,
R5 denotes H,
R6 denotes -CEC-R4
and
R4 has the meaning described herein,
is reacted with N-chlorosuccinimide,
or
d) for the preparation of a compound of the formula lb'
R3
lb'
Rs s R6
in which
R3 denotes NH-000-tert-butyl,
R5 denotes (CH2)õHet3,
R6 denotes -CEC-R4
and
n, R4 and Het3 have the meanings described herein,
a compound of the formula lb"
CA 2784067 2017-08-03
81565053
- 18 -
R3
lb"
R5 R6
in which
R3 denotes NH-000-tert-butyl,
R6 denotes CI,
R6 denotes -CC-R4
and
R4 has the meaning described herein,
is reacted with a compound of the formula IVa
L-(CH2)nR5
in which R5 denotes Het3,
n and Het3 have the meanings described herein,
and L denotes a boronic acid or boronic acid ester radical,
and subsequently or simultaneously the Boc group is cleaved off,
or
e) for the preparation of a compound of the formula la"
R7
zN
R1 la"
R2
CA 2784067 2017-08-03
81565053
- 19 -
in which
R1 denotes Ar or Het,
R2 denotes H, Cl, (CH2)õHet3
R7 denotes H,
and Ar, Het and Het3 have the meanings described herein,
a compound of the formula lb'
R3
Ib'
R6 R6
in which
R3 denotes NH-000-tert-butyl,
R5 denotes H, Cl, (CH2)r,Het3,
R6 denotes -CE-C-R4
R4 denotes Ar or Het,
and n, Ar, Het, Het3 and R4 have the meanings described
herein,
is heated in the presence of a base,
= or
for the preparation of a compound of the formula la"
R7
/N
R1 la"
R2
=
CA 2784067 2017-08-03
81565053
- 20 -
in which
R1 denotes Ar or Het,
R2 denotes Heti
R7 denotes H ,
a compound of the formula la"
R7
1
N
\la"
R2
in which
Ri denotes Ar or Het,
R2 denotes Hal
R7 denotes H,
Ar and Het have the meanings described herein,
is reacted with a compound of the formula Va
Heti-H Va
in which Heti has the meaning described herein,
and/or
a base or acid of the formula la or lb is converted into one of its salts.
CA 2784067 2017-08-03
CA 02784067 2012-06-12
WO 2011/0727'79
PCT/EP2010/006822
- 21 -
Above and below, the radicals R1, R1', R2, R3, R5, R6 and R7 have the
meanings indicated for the formulae la and lb, unless expressly indicated
otherwise.
For all radicals which occur more than once, their meanings are independ-
ent of one another.
A denotes alkyl, is unbranched (linear) or branched, and has 1, 2, 3, 4, 5,
6, 7, 8, 9 or 10 C atoms. A preferably denotes methyl, furthermore ethyl,
= 10 propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-
butyl, furthermore also
pentyl, 1-, 2- or 3-methylbutyl, 1,1- , 1,2- or 2,2-dimethylpropyl, 1-ethyl-
.
propyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3- , 2,2-, 2,3- or
3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethy1-1-methylpropyl, 1-ethy1-2-
methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, furthermore preferably, for
example, trifluoromethyl.
A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C
atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-
butyl,
tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl or 1,1,1-
trifluoro-
ethyl.
A also denotes unbranched or branched alkyl having 1-10 C atoms, in which
1-7 H atoms may be replaced by OH, F, Cl and/or Br.
A furthermore denotes, for example, 2-hydroxyethyl, 3-hydroxypropyl, 2-
methoxyethyl or 3-methoxypropyl.
Cyclic alkyl (cycloalkyl) preferably denotes cyclopropyl, cyclobutyl, cyclo-
pentyl, cyclohexyl or cycloheptyl.
A' denotes alkyl, this is unbranched (linear) or branched, and has 1, 2, 3, 4,
5
or 6 C atoms. A' preferably denotes methyl, furthermore ethyl, propyl, iso-
propyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-,
2- or
3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-,
3- or 4-methylpentyl, 1,1- , 1,2- , 1,3- ,
2,2- , 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethy1-1-methylpropyl,
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 22 -
1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, furthermore prefera-
bly, for example, trifluoromethyl.
A' very particularly preferably denotes methyl, ethyl, propyl, isopropyl,
butyl,
isobutyl, sec-butyl, tert-butyl, pentyl, hexyl or trifluoromethyl.
R1 preferably denotes 4-fluorophenyl, benzyl, 3-aminophenyl,
3-(benzylamino)phenyl or 2-aminopyridin-4-yl.
RI' preferably denotes H.
R2 preferably denotes H, Hal, Heti or -CC-Ar.
R3 preferably denotes NHCOOA' or NH2.
R6 preferably denotes H.
R6 preferably denotes H, 4-fluorophenylethynyl, 3-phenylprop-1-ynyl, triethyl-
silanylethynyl, 3-aminophenylethynyl, 3-benzylaminophenylethynyl, 2-benzyl-
aminopyridin-4-ylethynyl, pyrrolo[2,3-13}pyridin-5-ylethynyl, Hal, 3-morpholin-
4-
ylprop-1-ynyl, 3-(1,3-dioxo-1,3-dihydroisoindo1-2-yl)prop-1-ynyl or 3-hydroxy-
phenylethynyl.
R7 preferably denotes H.
Ar denotes, for example, phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl,
o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butyl-
phenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-
aminophenyl, o-, m- or p-(N-methylamino)phenyl, o-, m- or p-(N-methyl-
aminocarbonyl)phenyl, o-, m- or p-acetamidophenyl, o-, m- or p-methoxy-
phenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-ethoxycarbonylphenyl, o-, m-
or p-(N,N-dimethylamino)phenyl, o-, m- or p-(N,N-dimethylaminocarbonyI)-
phenyl, o-, m- or p-(N-ethylamino)phenyl, o-, m- or p-(N,N-diethylamino)-
phenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p-
chlorophenyl, o-, m- or p-(methylsulfonamido)phenyl, o-, m- or p-(methyl-
sulfonyl)phenyl, o-, m- or p-cyanophenyl, o-, m- or p-carboxyphenyl, o-, m-
or p-methoxycarbonylphenyl, o-, m- or p-aminosulfonylphenyl, o-, m- or p-
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 23 -
(benzylamino)phenyl furthermore preferably 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or
3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-,
2,4-, 2,5-, 2,6-, 3,4- or 3,5-dibromophenyl, 2,4- or 2,5-dinitrophenyl, 2,5-
or
3,4-dimethoxyphenyl, 3-nitro-4-chlorophenyl, 3-amino-4-chloro-, 2-amino-
3-chloro-, 2-amino-4-chloro-, 2-amino-5-chloro- or 2-amino-6-chlorophenyl,
2-nitro-4-N,N-dimethylamino- or 3-nitro-4-N,N-dimethylaminophenyl, 2,3-
diaminophenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, 2,4,6-
trimethoxyphenyl, 2-hydroxy-3,5-dichlorophenyl, p-iodophenyl, 3,6-di-
chloro-4-aminophenyl, 4-fluoro-3-chlorophenyl, 2-fluoro-4-bromophenyl,
2,5-difluoro-4-bromophenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6-meth-
oxyphenyl, 3-chloro-4-acetamidophenyl, 3-fluoro-4-methoxyphenyl, 3-
amino-6-methylphenyl, 3-chloro-4-acetamidophenyl or 2,5-dimethy1-4-
chlorophenyl.
Ar particularly preferably denotes phenyl which is unsubstituted or mono-, di-
or trisubstituted by Hal, A, OH, OA, CN, NO2, SO2A, COOH, COOA, NH2,
NHA, NA2, NHCH2Ar1, CHO, COA, CHO, CONH2, CONHA, CONA2, SO2NH2,
SO2NHA and/or NHCOA.
Ar very particularly preferably denotes phenyl which is unsubstituted or mono-
,
di- or trisubstituted by Hal, A, OH, OA, NH2, NHA, NA2 and/or NHCH2Ar1
.
Arl preferably denotes phenyl.
Irrespective of further substitutions, Het denotes, for example, 2- or 3-
furyl,
2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4-
or 5-
pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-
thiazolyl, 3-,
4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl,
further-
more preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl,
1-
or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl,
1,3,4-
thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -
5-yl,
3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-
iso-
indolyl, indazolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-
benzo-
pyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-
benzisoxazolyl,
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 24 -
2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-,
5-,
6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-,
4-,
5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-
, 7- or
8-quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-
oxazinyl, pyrrolopyridinyl, purinyl, further preferably 1,3-benzodioxo1-5-yl,
1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4-, -5-ylor 2,1,3-benzoxa-
diazol-5-y1 or dibenzofuranyl.
Het particularly preferably denotes furyl, thienyl, pyrrolyl, imidazolyl,
pyrazolyl,
oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl,
triazolyl, tetra-
zolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, benzimidazolyl,
benzo-
triazolyl, quinolinyl, quinoxalinyl, quinazolinyl, pyrrolopyridinyl, purinyl,
indolyl
or indazolyl, each of which is unsubstituted or mono- or disubstituted by NH2
and/or NHCH2Ar1
.
Irrespective of further substitutions, Heti denotes, for example, 2- or 3-
furyl, 2-
or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-
pyra-
zolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-
, 4- or
5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore
pref-
erably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 1- or 5-
tetrazolyl,
1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2-
or -5-
yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-
pyridazinyl,
pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, indazolyl,
1-, 2-, 4-
or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or
7-
benzoxazolyl, 3-, 4-, 5-, 6- or 7- benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzo-
thiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-
oxa-
diazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-
isoquinolyl,
3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5-
or 6-quin-
oxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, pyrrolopyridinyl,
purinyl,
further preferably 1,3-benzodioxo1-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothia-
diazol-4- or -5-yl, 2,1,3-benzoxadiazol-5-yl, azabicyclo[3.2.11-octyl or
dibenzo-
furanyl.
The heterocyclic radicals may also be partially or fully hydrogenated.
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 25 -
Irrespective of further substitutions, Heti can thus also denote, for exam-
ple, 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-
furyl,
tetrahydro-2- or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-
dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro 1 , 2 , 3 , 4 or -5-
pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-
dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl,
1,4-dihydro 1 , 2 , 3 or -4-pyridyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-
or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-rnorpholinyl,
tetrahydro-
2_, -3- or -4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-, -4- or -5-yl, hexahydro-1-
,
-3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-
piperazinyl, 1,2,34-tetrahydro 1 , 2, 3 , 4, 5 , 6 , 7 or -8-quinolyl,
1,2,3,4-tetrahydro-1 , 2-, 3 , -4 , 5 , 6 , 7 or -8-isoquinolyl, 2-, 3-, 5-,
6-,
7- or 8- 3,4-dihydro-2H-benzo-1,4-oxazinyl, furthermore preferably 2,3-
methylenedioxyphenyl, 3,4-methylenedioxyphenyl, 2,3-ethylenedioxy-
phenyl, 3,4-ethylenedioxyphenyl, 3,4-(difluoromethylenedioxy)phenyl, 2,3-
dihydrobenzofuran-5- or 6-yl, 2,3-(2-oxomethylenedioxy)phenyl or also 3,4-
dihydro-2H-1,5-benzodioxepin-6- or -7-yl, furthermore preferably 2,3-
dihydrobenzofuranyl, 2,3-dihydro-2-oxofuranyl, 3,4-dihydro-2-oxo-1 H-
quinazolinyl, 2,3-dihydrobenzoxazolyl, 2-oxo-2,3-dihydrobenzoxazolyl, 2,3-
dihydrobenzimidazolyl, 1,3-dihydroindole, 2-oxo-1,3-dihydroindole or 2-
oxo-2,3-dihydrobenzimidazolyl.
Heti particularly preferably denotes piperidinyl, pyrrolidinyl, morpholinyl,
piperazinyl, imidazolidinyl, oxazolidinyl, tetrahydropyranyl, thiazolyl,
thiophenyl,
furanyl, pyrrolyl, oxazolyl, isoxazolyl, oxadiazolyl, pyrazolyl, imidazolyl,
tri-
azolyl, thiadiazolyl, pyridazinyl, pyrazinyl, pyridinyl or pyrimidinyl, each
of
which is unsubstituted or mono- or disubstituted by NH2 and/or CH2Het2.
Irrespective of further substitutions, Het2 denotes, for example, 2- or 3-
furyl, 2-
or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-
pyrazo-
lyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-,
4- or 5-
isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore
pref-
erably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-
CA 02784067 2012-06-12
WO 2011/0727'79 PCT/EP2010/006822
- 26 -
1-, -3- or 5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-
oxadiazol-3-
or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-
thiadiazol-
4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-
indolyl, 4- or
5-isoindolyl, indazolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or
7-
benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-
benzisoxa-
zolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-
benzisothiazolyl, 4-, 5-,
6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-,
4-, 5-,
6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7-
or 8-
quinazolinyl, 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-
oxazinyl,
pyrrolopyridinyl, purinyl, further preferably 1,3-benzodioxo1-5-yl, 1,4-benzo-
dioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl, 2,1,3-benzoxadiazol-5-ylor
dibenzofuranyl.
Het2 particularly preferably denotes furyl, thienyl, pyrrolyl, imidazolyl,
pyrazolyl,
oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl,
triazolyl, tetra-
zolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, benzimidazolyl,
benzo-
triazolyl, quinolinyl, quinoxalinyl, quinazolinyl, pyrrolopyridinyl, purinyl,
indolyl
or indazolyl, each of which is unsubstituted or mono- or disubstituted by A
and/or NF12.
Irrespective of further substitutions, Het3 denotes, for example, 2- or 3-
furyl, 2-
or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-
pyra-
zolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-
, 4- or
5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore
pref-
erably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 1- or 5-
tetrazolyl,
1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2-
or -5-
yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-
pyridazinyl,
pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, indazolyl,
1-, 2-, 4-
or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or
7-
benzoxazolyl, 3-, 4-, 5-, 6- or 7- benzisoxazolyl, 2-, 4-, 5-, 6- or 7-
benzothiazo-
lyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-
oxadiazolyl, 2-,
3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-,
4-, 5-, 6-,
7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-
quinoxalinyl, 2-, 3-,
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 27 -
5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, pyrrolopyridinyl, purinyl, further
prefera-
bly 1,3-benzodioxo1-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-
yl, 2,1,3-benzoxadiazol-5-ylor dibenzofuranyl.
Het3 particularly preferably denotes furyl, thienyl, pyrrolyl, imidazolyl,
pyrazolyl,
oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl,
triazolyl, tetra-
zolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyrazinyl, benzimidazolyl,
benzo-
triazolyl, quinolinyl, quinoxalinyl, quinazolinyl, pyrrolopyridinyl, purinyl,
indolyl
or indazolyl, each of which is unsubstituted or mono- or disubstituted by A
and/or NH2
Irrespective of further substitutions, Hee denotes, for example, 2- or 3-
furyl, 2-
or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-
pyra-
zolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-
, 4- or
5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore
pref-
erably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 1- or 5-
tetrazolyl,
1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2-
or -5-
yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-
pyridazinyl,
pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, indazolyl,
1-, 2-, 4-
or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or
7-
benzoxazolyl, 3-, 4-, 5-, 6- or 7- benzisoxazolyl, 2-, 4-, 5-, 6- or 7-
benzothiazo-
lyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-
oxadiazolyl, 2-,
3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-,
4-, 5-, 6-,
7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-
quinoxalinyl, 2-, 3-,
5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, pyrrolopyridinyl, purinyl, further
prefera-
bly 1,3-benzodioxo1-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-
yl, 2,1,3-benzoxadiazol-5-yl, azabicyclo[3.2.1]-octyl or dibenzofuranyl.
The heterocyclic radicals may also be partially or fully hydrogenated.
Irrespective of further substitutions, Het4 can thus also denote, for example,
2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl,
tetrahydro-
2- or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-
, -2-,
-3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2-
or 3-pyr-
rolidinyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4-
or -5-
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 28 -
pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1,4-dihydro 1 , 2 , 3 or -4-
pyridyl,
1,2,3,4-tetrahydro -- 1 , 2 , 3 , 4 , 5 or 6-pyridyl, 1-, 2-, 3- or 4-
piperidinyl, 2-,
3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1,4-dioxanyl, 1,3-
dioxan-2-
, -4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or
-5-
pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-
, -6-,
-7- or -8-quinolyl, 1,2,3,4-tetrahydro-1-,-2-,-3-, -4-, -5-, -6-, -7- or -8-
isoquinolyl,
2-, 3-, 5-, 6-, 7- or 8- 3,4-dihydro-2H-benzo-1,4-oxazinyl, further preferably
2,3-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, 2,3-ethylenedioxy-
phenyl, 3,4-ethylenedioxyphenyl, 3,4-(difluoromethylenedioxy)phenyl, 2,3-
dihydrobenzofuran-5- or 6-yl, 2,3-(2-oxomethylenedioxy)phenyl or also 3,4-
dihydro-2H-1,5-benzodioxepin-6- or -7-yl, furthermore preferably 2,3-dihydro-
benzofuranyl, 2,3-dihydro-2-oxofuranyl, 3,4-dihydro-2-oxo-1H-quinazolinyl,
2,3-dihydrobenzoxazolyl, 2-oxo-2,3-dihydrobenzoxazolyl, 2,3-dihydrobenz-
imidazolyl, 1,3-dihydroindole, 2-oxo-1,3-dihydroindole or 2-oxo-2,3-dihydro-
benzimidazolyl.
Hee particularly preferably denotes piperidinyl, pyrrolidinyl, morpholinyl,
piperazinyl, imidazolidinyl, oxazolidinyl, tetrahydropyranyl,
dihydroisoindolyl,
furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl,
thiazolyl,
isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl,
thiadiazolyl,
pyridazinyl, pyrazinyl, benzimidazolyl, benzotriazolyl, quinolinyl,
quinoxalinyl,
quinazolinyl, pyrrolopyridinyl, purinyl, indolyl or indazolyl, each of which
is
unsubstituted or mono- or disubstituted by NH2, NHCH2Ar1 and/or O.
Hal preferably denotes F, Cl or Br, but also I, particularly preferably F or
CI; m
preferably denotes 1 or 2; n preferably denotes 0, 1, 2 or 3.
Throughout the invention, all radicals which occur more than once may be
identical or different, i.e. are independent of one another.
The compounds of the formula la and lb may have one or more chiral
centres and can therefore occur in various stereoisomeric forms. The for-
mula la and lb encompasses all these forms.
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 29 -
Accordingly, the invention relates, in particular, to the compounds of the
formula la and lb in which at least one of the said radicals has one of the
preferred meanings indicated above. Some preferred groups of com-
pounds may be expressed by the following sub-formulae laa to laj, which
conform to the formula la and lb and in which the radicals not designated
in greater detail have the meaning indicated for the formula la and lb, but
in which
in laa Ar denotes phenyl which is unsubstituted or mono-, di- or
trisubstituted by Hal, OH, OA, NH2, NHA, NA2 and/or
NHCH2Arl;
in lab Het denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazo-
lyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, tri-
azolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyra-
zinyl, benzimidazolyl, benzotriazolyl, quinolinyl, quinoxalinyl,
quinazolinyl, pyrrolopyridinyl, purinyl, indolyl or indazolyl,
each of which is unsubstituted or mono- or disubstituted by
NH2 and/or NHCH2Ar1;
in lac Arl denotes phenyl;
in lad Het' denotes piperidinyl, pyrrolidinyl, morpholinyl,
piperazinyl,
imidazolidinyl, oxazolidinyl, tetrahydropyranyl, thiazolyl,
thiophenyl, furanyl, pyrrolyl, oxazolyl, isoxazolyl, oxadia-
zolyl, pyrazolyl, imidazolyl, triazolyl, thiadiazolyl, pyridazinyl,
pyrazinyl, pyridinyl or pyrimidinyl, each of which is unsubsti-
tuted or mono- or disubstituted by NH2 and/or CH2Het2;
in lae Het2 denotes fury!, thienyl, pyrrolyl, imidazolyl, pyrazolyl,
oxazo-
lyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, tri-
azolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl,
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 30 -
pyrazinyl, benzimidazolyl, benzotriazolyl, quinolinyl, quin-
oxalinyl, quinazolinyl, pyrrolopyridinyl, purinyl, indolyl or
indazolyl, each of which is unsubstituted or mono- or disub-
stituted by A and/or NH2;
in laf Het3 denotes furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl,
oxa-
zolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimi-
dinyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyri-
dazinyl, pyrazinyl, benzimidazolyl, benzotriazolyl, quino-
linyl, quinoxalinyl, quinazolinyl, pyrrolopyridinyl, purinyl,
indolyl or indazolyl, each of which is unsubstituted or
mono- or disubstituted by A and/or NH2;
in lag Het4 denotes piperidinyl, pyrrolidinyl, morpholinyl,
piperazinyl,
imidazolidinyl, oxazolidinyl, tetrahydropyranyl, dihydroiso-
indolyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl,
isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, tri-
azolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridazinyl, pyra-
zinyl, benzimidazolyl, benzotriazolyl, quinolinyl, quinoxalinyl,
quinazolinyl, pyrrolopyridinyl, purinyl, indolyl or indazolyl,
each of which is unsubstituted or mono- or disubstituted by
NH2, NHCH2Ar1 and/or =0;
in lah R1 denotes H, (CH2),Ar or (CH2),Het,
R1' denotes H,
R2 denotes H, Hal, (CH2)nHet1, (CH2)nHet3 or -CEC-Ar,
R3 denotes NHCOOA' or NH2,
R4 denotes (CH2),Ar, SiA3 or (CH2)nHet4,
R6 denotes H or (CH2),Het3,
R6 denotes H, -CEC-R4 or Hal,
R7 denotes H,
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 31 -
Ar denotes phenyl which is unsubstituted or mono-, di- or
trisubstituted by Hal, A, OH, OA, CN, NO2, SO2A, COOH,
COOA, NH2, NHA, NA2, NHCH2Ar1, CHO, COA, CHO,
CONH2, CONHA, CONA2, SO2NH2, SO2NHA and/or
NHCOA,
Het denotes a mono- or bicyclic aromatic heterocycle having
1
to 4 N, 0 and/or S atoms, which may be unsubstituted or
mono-, di- or trisubstituted by Hal, A, NH2 and/or
NHCH2Ar1
,
Ari denotes phenyl which is unsubstituted or mono-, di- or
tri-
substituted by Hal, A, OH and/or OA,
Heti denotes a mono- or bicyclic aromatic, unsaturated or
satu-
rated heterocycle having 1 to 4 N, O and/or S atoms, which
may be unsubstituted or mono-, di- or trisubstituted by Hal,
A, NH2 and/or CH2Het2,
Het2 denotes a mono- or bicyclic aromatic heterocycle having
1
to 4 N, 0 and/or S atoms, which may be unsubstituted or
mono-, di- or trisubstituted by A and/or NH2,
Het3 denotes a mono- or bicyclic aromatic heterocycle having
1
to 4 N, 0 and/or S atoms, which may be unsubstituted or
mono-, di- or trisubstituted by NH2,
Het4 denotes a mono- or bicyclic aromatic, unsaturated or satu-
rated heterocycle having 1 to 4 N, O and/or S atoms, which
may be unsubstituted or mono-, di- or trisubstituted by Hal,
A, NH2, NHCH2Ar1 and/or =0,
A denotes unbranched or branched alkyl having 1-10 C
atoms,
in which 1-7 H atoms may be replaced by OH, F, Cl and/or
Br,
A' denotes unbranched or branched alkyl having 1-4 C atoms,
Hal denotes F, Cl, Br or I,
denotes 0, 1, 2, 3 or 4;
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 32 -
and pharmaceutically usable salts, tautomers and stereoisomers thereof,
including mixtures thereof in all ratios.
The compounds of the formula la and lb and also the starting materials for
their preparation are, in addition, prepared by methods known per se, as
described in the literature (for example in the standard works, such as
Houben-Weyl, Methoden der organischen Chemie [Methods of Organic
Chemistry], Georg-Thieme-Verlag, Stuttgart), to be precise under reaction
conditions which are known and suitable for the said reactions. Use can
also be made here of variants known per se which are not mentioned here
in greater detail.
Compounds of the formula la' can preferably be obtained by reacting a com-
pound of the formula Ilc with a compound of the formula 111c.
The starting compounds of the formulae Ilc and IIIc are generally known. If
they are novel, however, they can be prepared by methods known per se.
The reaction is carried out under conditions as are known to the person
skilled
in the art for an amino-palladation reaction reaction (Example 1). Diverse
catalysts can be used.
Depending on the conditions used, the reaction time is between a few
minutes and 14 days, the reaction temperature is between about -30' and
140 , normally between 30 and 1200, in particular between about 60 and
about 90 .
Suitable inert solvents are, for example, hydrocarbons, such as hexane,
petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons,
such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloro-
form or dichloromethane; alcohols, such as methanol, ethanol, isopropa-
nol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether,
diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as
ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl
ether (diglyme); ketones, such as acetone or butanone; amides, such as
CA 02784067 2012-06-12
WO 2011/072779 PCTXP2010/006822
- 33 -
acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such
as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMS0); carbon di-
sulfide; carboxylic acids, such as formic acid or acetic acid; nitro com-
pounds, such as nitromethane or nitrobenzene; esters, such as ethyl ace-
tate, or mixtures of the said solvents.
Particular preference is given to DMF.
Compounds of the formula lb' can preferably be obtained by reacting a com-
pound of the formula Ild with a compound of the formula 111d.
The starting compounds of the formulae Ild and Illd are generally known. If
they are novel, however, they can be prepared by methods known per se.
The reaction is carried out under conditions as are known to the person
skilled
in the art for a Sonogashira reaction (Example 2). Diverse catalysts can be
used.
Depending on the conditions used, the reaction time is between a few
minutes and 14 days, the reaction temperature is between about -30 and
1400, normally between 10 and 1000, in particular between about 200 and
about 80 .
Suitable inert solvents are, for example, hydrocarbons, such as hexane,
petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons,
such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloro-
form or dichloromethane; alcohols, such as methanol, ethanol, isopropa-
nol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether,
diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as
ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl
ether (diglyme); ketones, such as acetone or butanone; amides, such as
acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such
as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMS0); carbon di-
sulfide; carboxylic acids, such as formic acid or acetic acid; nitro com-
pounds, such as nitromethane or nitrobenzene; esters, such as ethyl ace-
tate, or mixtures of the said solvents.
Particular preference is given to tetrahydrofuran.
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 34 -
Compounds of the formula lb" in which R5 denotes chlorine can preferably be
obtained by reacting a compound of the formula lb" in which R5 denotes H
with N-chlorosuccinimide (Example 3).
The reaction is preferably carried out in THF at -78 C after prior addition of
BuLi in n-hexane.
Compounds of the formula lb' in which R5 denotes Het3 can preferably be
obtained by reacting a compound of the formula lb" in which R5 denotes chlo-
rine with a compound of the formula IVa (Example 4).
The reaction is carried out under conditions as are known to the person
skilled
in the art for a Suzuki reaction.
In the compounds of the formula IVa, L preferably denotes
HO
)3¨
f Or B¨ .
HO 0
The reaction is carried out under standard conditions of a Suzuki coupling.
Depending on the conditions used, the reaction time is between a few
minutes and 14 days, the reaction temperature is between about -30 and
140 , normally between 0 and 100 , in particular between about 600 and
about 90".
Suitable inert solvents are, for example, hydrocarbons, such as hexane,
petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons,
such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloro-
form or dichloromethane; alcohols, such as methanol, ethanol, isopropa-
nol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether,
diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as
ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl
ether (diglyme); ketones, such as acetone or butanone; amides, such as
acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 35 -
as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMS0); carbon di-
sulfide; carboxylic acids, such as formic acid or acetic acid; nitro com-
pounds, such as nitromethane or nitrobenzene; esters, such as ethyl ace-
tate, or mixtures of the said solvents.
Particular preference is given to ethanol, toluene, dimethoxyethane and/or
water.
Compounds of the formula la" can also preferably be obtained by heating a
compound of the formula lb" in the presence of a base (Example 5). A suit-
able base is preferably potassium tert-butoxide.
Depending on the conditions used, the reaction time is between a few
minutes and 14 days, the reaction temperature is between about -30 and
1400, normally between 30 and 120 , in particular between about 800 and
about 1100
.
Suitable inert solvents are, for example, hydrocarbons, such as hexane,
petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons,
such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloro-
form or dichloromethane; alcohols, such as methanol, ethanol, isopropa-
nol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether,
diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as
ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl
ether (diglyme); ketones, such as acetone or butanone; amides, such as
acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such
as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMS0); carbon di-
sulfide; carboxylic acids, such as formic acid or acetic acid; nitro com-
pounds, such as nitromethane or nitrobenzene; esters, such as ethyl ace-
tate, or mixtures of the said solvents.
Particular preference is given to NMP (N-methylpyrrolidone).
Furthermore, compounds of the formula lb" can be obtained by reacting a
compound of the formula lb" in which R2 denotes Hal, such as, for example,
chlorine, with a compound of the formula Va (Example 6).
81565053
- 36 -
Depending on the conditions used, the reaction time is between a few
minutes and 14 days, the reaction temperature is between about 0 and
140 , normally between 30 and 140 , in particular between about 80 and
about 130 .
The reaction is carried out with or without solvents.
Analogously to process step e), the compounds of the formula la" according to
the invention
R7
yN
R1 la"
R2
in which
R1 denotes Ar or Het,
R7 denotes H,
and R2, Ar, Het have the meanings described herein,
are obtained by heating a compound of the formula lb'
R3
I b'
R2 R6
in which
R3 denotes NH-000-tert-butyl,
R6 denotes -CEC-R4
R4 denotes Ar or Het,
and Ar, Het, R2 and R4 have the meanings described herein,
CA 2784067 2017-08-03
CA 02784067 2012-06-12
WO 2011/072779
PCPEP2010/006822
- 37 -
in the presence of a base (Example 5).
Furthermore, free amino groups can be acylated in a conventional manner
using an acid chloride or anhydride or alkylated using an unsubstituted or
substituted alkyl halide, advantageously in an inert solvent, such as
dichloromethane or THF, and /or in the presence of a base, such as tri-
ethylamine or pyridine, at temperatures between -60 and +30 .
The compounds of the formulae la and lb can furthermore be obtained by
liberating them from their functional derivatives by solvolysis, in particular
hydrolysis, or by hydrogenolysis.
Preferred starting materials for the solvolysis or hydrogenolysis are those
which contain corresponding protected amino and/or hydroxyl groups in-
stead of one or more free amino and/or hydroxyl groups, preferably those
which carry an amino-protecting group instead of an H atom bonded to an
N atom, for example those which conform to the formula la and lb, but
contain an NHR' group (in which R' is an amino-protecting group, for
example BOC or CBZ) instead of an NH2 group.
Preference is furthermore given to starting materials which carry a
hydroxyl-protecting group instead of the H atom of a hydroxyl group, for
example those which conform to the formula la and lb, but contain an R"0-
phenyl group (in which R" is a hydroxyl-protecting group) instead of a
hydroxyphenyl group.
It is also possible for a plurality of - identical or different - protected
amino
and/or hydroxyl groups to be present in the molecule of the starting mate-
rial. If the protecting groups present are different from one another, they
can in many cases be cleaved off selectively.
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 38 -
The term "amino-protecting group" is known in general terms and relates
to groups which are suitable for protecting (blocking) an amino group
against chemical reactions, but are easy to remove after the desired
chemical reaction has been carried out elsewhere in the molecule. Typical
of such groups are, in particular, unsubstituted or substituted acyl, aryl,
aralkoxymethyl or aralkyl groups. Since the amino-protecting groups are
removed after the desired reaction (or reaction sequence), their type and
size are furthermore not crucial; however, preference is given to those hav-
ing 1-20, in particular 1-8, carbon atoms. The term "acyl group" is to be
understood in the broadest sense in connection with the present process.
= It includes acyl groups derived from aliphatic, araliphatic, aromatic or
heterocyclic carboxylic acids or sulfonic acids, and, in particular, alkoxy-
carbonyl, aryloxycarbonyl and especially aralkoxycarbonyl groups. Exam-
ples of such acyl groups are alkanoyl, such as acetyl, propionyl and
butyryl, aralkanoyl, such as phenylacetyl; aroyl, such as benzoyl and toly1;
aryloxyalkanoyl, such as POA; alkoxycarbonyl, such as methoxycarbonyl,
ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC and 2-iodoethoxy-
carbonyl; aralkoxycarbonyl, such as CBZ (''carbobenzoxy"), 4-methoxy-
benzyloxycarbonyl and FMOC; and arylsulfonyl, such as Mtr, Pbf and Pmc.
Preferred amino-protecting groups are BOC and Mtr, furthermore CBZ,
Fmoc, benzyl and acetyl.
The term "hydroxyl-protecting group" is likewise known in general terms
and relates to groups which are suitable for protecting a hydroxyl group
against chemical reactions, but are easy to remove after the desired
chemical reaction has been carried out elsewhere in the molecule. Typical
of such groups are the above-mentioned unsubstituted or substituted aryl,
aralkyl or acyl groups, furthermore also alkyl groups. The nature and size
of the hydroxyl-protecting groups are not crucial since they are removed
again after the desired chemical reaction or reaction sequence; preference
is given to groups having 1-20, in particular 1-10, carbon atoms. Examples
of hydroxyl-protecting groups are, inter alia, tert-butoxycarbonyl, benzyl,
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 39 -
p-nitrobenzoyl, p-toluenesulfonyl, tert-butyl and acetyl, where benzyl and
tert-butyl are particularly preferred. The COOH groups in aspartic acid and
glutamic acid are preferably protected in the form of their tert-butyl esters
(for example Asp(OBut)).
The compounds of the formula la and lb are liberated from their functional
derivatives ¨ depending on the protecting group used ¨ for example using
strong acids, advantageously using TFA or perchloric acid, but also using
other strong inorganic acids, such as hydrochloric acid or sulfuric acid,
strong organic carboxylic acids, such as trichloroacetic acid, or sulfonic
acids, such as benzene- or p-toluenesulfonic acid. The presence of an
additional inert solvent is possible, but is not always necessary. Suitable
inert solvents are preferably organic, for example carboxylic acids, such as
acetic acid, ethers, such as tetrahydrofuran or dioxane, amides, such as
DMF, halogenated hydrocarbons, such as dichloromethane, furthermore
also alcohols, such as methanol, ethanol or isopropanol, and water. Mix-
tures of the above-mentioned solvents are furthermore suitable. TFA is
preferably used in excess without addition of a further solvent, and per-
chloric acid is preferably used in the form of a mixture of acetic acid and
70% perchloric acid in the ratio 9:1. The reaction temperatures for the
cleavage are advantageously between about 0 and about 50 , preferably
between 15 and 30 (room temperature).
The BOC, 0But, Pbf, Pmc and Mtr groups can, for example, preferably be
cleaved off using TFA in dichloromethane or using approximately 3 to 5N
HCI in dioxane at 15-30 , and the FMOC group can be cleaved off using
an approximately 5 to 50% solution of dimethylamine, diethylamine or
piperidine in DMF at 15-30 .
Hydrogenolytically removable protecting groups (for example CBZ or
benzyl) can be cleaved off, for example, by treatment with hydrogen in the
presence of a catalyst (for example a noble-metal catalyst, such as palla-
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 40 -
dium, advantageously on a support, such as carbon). Suitable solvents
here are those indicated above, in particular, for example, alcohols, such
as methanol or ethanol, or amides, such as DMF. The hydrogenolysis is
generally carried out at temperatures between about 0 and 1000 and pres-
sures between about 1 and 200 bar, preferably at 20-30' and 1-10 bar.
Hydrogenolysis of the CBZ group succeeds well, for example, on 5 to 10%
Pd/C in methanol or using ammonium formate (instead of hydrogen) on
Pd/C in methanol/DMF at 20-30 .
Pharmaceutical salts and other forms
The said compounds according to the invention can be used in their final
non-salt form. On the other hand, the present invention also encompasses
the use of these compounds in the form of their pharmaceutically accept-
able salts, which can be derived from various organic and inorganic acids
and bases by procedures known in the art. Pharmaceutically acceptable
salt forms of the compounds of the formula la and lb are for the most part
prepared by conventional methods. If the compound of the formula la or lb
contains a carboxyl group, one of its suitable salts can be formed by react-
ing the compound with a suitable base to give the corresponding base-
addition salt. Such bases are, for example, alkali metal hydroxides, includ-
ing potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline
earth metal hydroxides, such as barium hydroxide and calcium hydroxide;
alkali metal alkoxides, for example potassium ethoxide and sodium pro-
poxide; and various organic bases, such as piperidine, diethanolamine and
N-methylglutamine. The aluminium salts of the compounds of the formula
la and lb are likewise included. In the case of certain compounds of the
formula la and lb, acid-addition salts can be formed by treating these com-
pounds with pharmaceutically acceptable organic and inorganic acids, for
example hydrogen halides, such as hydrogen chloride, hydrogen bromide
or hydrogen iodide, other mineral acids and corresponding salts thereof,
such as sulfate, nitrate or phosphate and the like, and alkyl- and monoaryl-
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
-41 -
sulfonates, such as ethanesulfonate, toluenesulfonate and benzene-
sulfonate, and other organic acids and corresponding salts thereof, such
as acetate, trifluoroacetate, tartrate, maleate, succinate, citrate, benzoate,
salicylate, ascorbate and the like. Accordingly, pharmaceutically accept-
able acid-addition salts of the compounds of the formula la and lb include
the following: acetate, adipate, alginate, arginate, aspartate, benzoate,
benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, cam-
phorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate,
cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitro-
.
benzoate, dodecylsulfate, ethanesulfonate, fumarate, galacterate (from
mucic acid), galacturonate, glucoheptanoate, gluconate, glutamate,
glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate,
hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethane-
sulfonate, iodide, isethionate, isobutyrate, lactate, lactobionate, malate,
maleate, malonate, mandelate, metaphosphate, methanesulfonate,
methylbenzoate, monohydrogenphosphate, 2-naphthalenesulfonate, nico-
tinate, nitrate, oxalate, oleate, palmoate, pectinate, persulfate, phenyl-
acetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this
does not represent a restriction.
Furthermore, the base salts of the compounds according to the invention
include aluminium, ammonium, calcium, copper, iron(111), iron(11), lithium,
magnesium, manganese(111), manganese(11), potassium, sodium and zinc
salts, but this is not intended to represent a restriction. Of the above-men-
tioned salts, preference is given to ammonium; the alkali metal salts
sodium and potassium, and the alkaline earth metal salts calcium and
magnesium. Salts of the compounds of the formula la and lb which are
derived from pharmaceutically acceptable organic non-toxic bases include
salts of primary, secondary and tertiary amines, substituted amines, also
including naturally occurring substituted amines, cyclic amines, and basic
ion exchanger resins, for example arginine, betaine, caffeine, chloro-
procaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclo-
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
-42 -
hexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-
dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine,
N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, iso-
propylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, mor-
pholine, piperazine, piperidine, polyamine resins, procaine, purines, theo-
bromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and
tris(hydroxymethyl)methylamine (tromethamine), but this is not intended to
represent a restriction.
Compounds of the present invention which contain basic nitrogen-contain-
ing groups can be quaternised using agents such as (Ci-C4)alkyl halides,
for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and
iodide; di(Ci-C4)alkyl sulfates, for example dimethyl, diethyl and diamyl
sulfate; (C10-C18)alkyl halides, for example decyl, dodecyl, lauryl, myristyl
and stearyl chloride, bromide and iodide; and aryl(C1-C4)alkyl halides, for
example benzyl chloride and phenethyl bromide. Both water- and oil-solu-
ble compounds according to the invention can be prepared using such
salts.
The above-mentioned pharmaceutical salts which are preferred include
acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisucci-
nate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, me-
glumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stea-
rate, sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and trometh-
amine, but this is not intended to represent a restriction.
Particular preference is given to hydrochloride, dihydrochloride, hydro-
bromide, maleate, mesylate, phosphate, sulfate and succinate.
The acid-addition salts of basic compounds of the formula la and lb are
prepared by bringing the free base form into contact with a sufficient
amount of the desired acid, causing the formation of the salt in a conven-
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 43 -
tional manner. The free base can be regenerated by bringing the salt form
into contact with a base and isolating the free base in a conventional man-
ner. The free base forms differ in a certain respect from the corresponding
salt forms thereof with respect to certain physical properties, such as solu-
bility in polar solvents; for the purposes of the invention, however, the
salts
otherwise correspond to the respective free base forms thereof.
As mentioned, the pharmaceutically acceptable base-addition salts of the
compounds of the formula la and lb are formed with metals or amines,
such as alkali metals and alkaline earth metals or organic amines. Pre-
ferred metals are sodium, potassium, magnesium and calcium. Preferred
organic amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline,
diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.
The base-addition salts of acidic compounds according to the invention are
prepared by bringing the free acid form into contact with a sufficient
amount of the desired base, causing the formation of the salt in a conven-
tional manner. The free acid can be regenerated by bringing the salt form
into contact with an acid and isolating the free acid in a conventional man-
ner. The free acid forms differ in a certain respect from the corresponding
salt forms thereof with respect to certain physical properties, such as solu-
bility in polar solvents; for the purposes of the invention, however, the
salts
otherwise correspond to the respective free acid forms thereof.
If a compound according to the invention contains more than one group
which is capable of forming pharmaceutically acceptable salts of this type,
the invention also encompasses multiple salts. Typical multiple salt forms
include, for example, bitartrate, diacetate, difumarate, dimeglumine, di-
phosphate, disodium and trihydrochloride, but this is not intended to repre-
sent a restriction.
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 44 -
With regard to that stated above, it can be seen that the expression "phar-
maceutically acceptable salt" in the present connection is taken to mean
an active ingredient which comprises a compound of the formula la and lb
in the form of one of its salts, in particular if this salt form imparts
improved
pharmacokinetic properties on the active ingredient compared with the free
form of the active ingredient or any other salt form of the active ingredient
used earlier. The pharmaceutically acceptable salt form of the active ingre-
dient can also provide this active ingredient for the first time with a
desired
pharmacokinetic property which it did not have earlier and can even have a
positive influence on the pharmacodynamics of this active ingredient with
respect to its therapeutic efficacy in the body.
The invention furthermore relates to medicaments comprising at least one
compound of the formula la and lb and/or pharmaceutically usable salts
and stereoisomers thereof, including mixtures thereof in all ratios, and
optionally excipients and/or adjuvants.
Pharmaceutical formulations can be administered in the form of dosage
units which comprise a predetermined amount of active ingredient per
dosage unit. Such a unit can comprise, for example, 0.5 mg to 1 g, prefer-
ably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a com-
pound according to the invention, depending on the condition treated, the
method of administration and the age, weight and condition of the patient,
or pharmaceutical formulations can be administered in the form of dosage
units which comprise a predetermined amount of active ingredient per
dosage unit. Preferred dosage unit formulations are those which comprise
a daily dose or part-dose, as indicated above, or a corresponding fraction
thereof of an active ingredient. Furthermore, pharmaceutical formulations
of this type can be prepared using a process which is generally known in
the pharmaceutical art.
CA 02784067 2012-06-12
WO 2011/072'779
PCT/EP2010/006822
- 45 -
Pharmaceutical formulations can be adapted for administration via any
desired suitable method, for example by oral (including buccal or sublin-
gual), rectal, nasal, topical (including buccal, sublingual or transdermal),
vaginal or parenteral (including subcutaneous, intramuscular, intravenous
or intradermal) methods. Such formulations can be prepared using all
processes known in the pharmaceutical art by, for example, combining the
active ingredient with the excipient(s) or adjuvant(s).
Pharmaceutical formulations adapted for oral administration can be admin-
istered as separate units, such as, for example, capsules or tablets; pow-
ders or granules; solutions or suspensions in aqueous or non-aqueous liq-
uids; edible foams or foam foods; or oil-in-water liquid emulsions or water-
in-oil liquid emulsions.
Thus, for example, in the case of oral administration in the form of a tablet
or capsule, the active-ingredient component can be combined with an oral,
non-toxic and pharmaceutically acceptable inert excipient, such as, for
example, ethanol, glycerol, water and the like. Powders are prepared by
comminuting the compound to a suitable fine size and mixing it with a
pharmaceutical excipient comminuted in a similar manner, such as, for
example, an edible carbohydrate, such as, for example, starch or mannitol.
A flavour, preservative, dispersant and dye may likewise be present.
Capsules are produced by preparing a powder mixture as described above
and filling shaped gelatine shells therewith. Glidants and lubricants, such
as, for example, highly disperse silicic acid, talc, magnesium stearate, cal-
cium stearate or polyethylene glycol in solid form, can be added to the
powder mixture before the filling operation. A disintegrant or solubiliser,
such as, for example, agar-agar, calcium carbonate or sodium carbonate,
may likewise be added in order to improve the availability of the medica-
ment after the capsule has been taken.
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 46 -
In addition, if desired or necessary, suitable binders, lubricants and disin-
tegrants as well as dyes can likewise be incorporated into the mixture.
Suitable binders include starch, gelatine, natural sugars, such as, for
example, glucose or beta-lactose, sweeteners made from maize, natural
and synthetic rubber, such as, for example, acacia, tragacanth or sodium
alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
The lubricants used in these dosage forms include sodium oleate, sodium
stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium
chloride and the like. The disintegrants include, without being restricted
thereto, starch, methylcellulose, agar, bentonite, xanthan gum and the like.
The tablets are formulated by, for example, preparing a powder mixture,
granulating or dry-pressing the mixture, adding a lubricant and a disinteg-
rant and pressing the entire mixture to give tablets. A powder mixture is
prepared by mixing the compound comminuted in a suitable manner with a
diluent or a base, as described above, and optionally with a binder, such
as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinyl-
pyrrolidone, a dissolution retardant, such as, for example, paraffin, an
absorption accelerator, such as, for example, a quaternary salt, and/or an
absorbant, such as, for example, bentonite, kaolin or dicalcium phosphate.
The powder mixture can be granulated by wetting it with a binder, such as,
for example, syrup, starch paste, acadia mucilage or solutions of cellulose
or polymer materials and pressing it through a sieve. As an alternative to
granulation, the powder mixture can be run through a tabletting machine,
giving lumps of non-uniform shape, which are broken up to form granules.
The granules can be lubricated by addition of stearic acid, a stearate salt,
talc or mineral oil in order to prevent sticking to the tablet casting moulds.
The lubricated mixture is then pressed to give tablets. The compounds
according to the invention can also be combined with a free-flowing inert
excipient and then pressed directly to give tablets without carrying out the
granulation or dry-pressing steps. A transparent or opaque protective layer
consisting of a shellac sealing layer, a layer of sugar or polymer material
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 47 -
and a gloss layer of wax may be present. Dyes can be added to these
coatings in order to be able to differentiate between different dosage units.
Oral liquids, such as, for example, solution, syrups and elixirs, can be pre-
pared in the form of dosage units so that a given quantity comprises a pre-
specified amount of the compound. Syrups can be prepared by dissolving
the compound in an aqueous solution with a suitable flavour, while elixirs
are prepared using a non-toxic alcoholic vehicle. Suspensions can be for-
mulated by dispersion of the compound in a non-toxic vehicle. Solubilisers
and emulsifiers, such as, for example, ethoxylated isostearyl alcohols and
polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as,
for example, peppermint oil or natural sweeteners or saccharin, or other
artificial sweeteners and the like, can likewise be added.
The dosage unit formulations for oral administration can, if desired, be en-
capsulated in microcapsules. The formulation can also be prepared in
such a way that the release is extended or retarded, such as, for example,
by coating or embedding of particulate material in polymers, wax and the
like.
The compounds of the formula la and lb and salts thereof can also be
administered in the form of liposome delivery systems, such as, for exam-
ple, small unilamellar vesicles, large unilamellar vesicles and multilamellar
vesicles. Liposomes can be formed from various phospholipids, such as,
for example, cholesterol, stearylamine or phosphatidylcholines.
The compounds of the formula la and lb and the salts thereof can also be
delivered using monoclonal antibodies as individual carriers to which the
compound molecules are coupled. The compounds can also be coupled to
soluble polymers as targeted medicament carriers. Such polymers may
encompass polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmeth-
acrylamidophenol, polyhydroxyethylaspartamidophenol or polyethylene
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 48 -
oxide polylysine, substituted by palmitoyl radicals. The compounds may
furthermore be coupled to a class of biodegradable polymers which are
suitable for achieving controlled release of a medicament, for example
polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, poly-
orthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates and
crosslinked or amphipathic block copolymers of hydrogels.
Pharmaceutical formulations adapted for transdermal administration can
be administered as independent plasters for extended, close contact with
the epidermis of the recipient. Thus, for example, the active ingredient can
be delivered from the plaster by iontophoresis, as described in general
terms in Pharmaceutical Res. 1986; 3 (6): 318 ff..
Pharmaceutical compounds adapted for topical administration can be for-
mulated as ointments, creams, suspensions, lotions, powders, solutions,
pastes, gels, sprays, aerosols or oils.
For the treatment of the eye or other external tissue, for example mouth
and skin, the formulations are preferably applied as topical ointment or
cream. In the case of formulation to give an ointment, the active ingredient
can be employed either with a paraffinic or a water-miscible cream base.
Alternatively, the active ingredient can be formulated to give a cream with
an oil-in-water cream base or a water-in-oil base.
Pharmaceutical formulations adapted for topical application to the eye
include eye drops, in which the active ingredient is dissolved or suspended
in a suitable carrier, in particular an aqueous solvent.
Pharmaceutical formulations adapted for topical application in the mouth
encompass lozenges, pastilles and mouthwashes.
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 49 -
Pharmaceutical formulations adapted for rectal administration can be ad-
ministered in the form of suppositories or enemas.
Pharmaceutical formulations adapted for nasal administration in which the
carrier substance is a solid comprise a coarse powder having a particle
size, for example, in the range 20-500 microns, which is administered in
the manner in which snuff is taken, i.e. by rapid inhalation via the nasal
passages from a container containing the powder held close to the nose.
Suitable formulations for administration as nasal spray or nose drops with
a liquid as carrier substance encompass active-ingredient solutions in
water or oil.
Pharmaceutical formulations adapted for administration by inhalation en-
compass finely particulate dusts or mists, which can be generated by vari-
ous types of pressurised dispensers with aerosols, nebulisers or insuffla-
tors.
Pharmaceutical formulations adapted for vaginal administration can be
administered as pessaries, tampons, creams, gels, pastes, foams or spray
formulations.
Pharmaceutical formulations adapted for parenteral administration include
aqueous and non-aqueous sterile injection solutions comprising antioxi-
dants, buffers, bacteriostatics and solutes, by means of which the formula-
tion is rendered isotonic with the blood of the recipient to be treated; and
aqueous and non-aqueous sterile suspensions, which may comprise sus-
pension media and thickeners. The formulations can be administered in
single-dose or multidose containers, for example sealed ampoules and
vials, and stored in freeze-dried (lyophilised) state, so that only the
addition
of the sterile carrier liquid, for example water for injection purposes, imme-
diately before use is necessary. Injection solutions and suspensions pre-
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 50 -
pared in accordance with the recipe can be prepared from sterile powders,
granules and tablets.
It goes without saying that, in addition to the above particularly mentioned
constituents, the formulations may also comprise other agents usual in the
respect e u ti c a n toy the effective particulara mo u nt typeof of
compound
o m formulation;po u n d o ft :hues f, foro rformula
example,ula ia o r b
for-
mulationsrt
which are suitable for oral administration may comprise flavours.
Aa with
he r ap
depends on a number of factors, including, for example, the age and
weight of the animal, the precise condition that requires treatment, and its
severity, the nature of the formulation and the method of administration,
and is ultimately determined by the treating doctor or vet. However, an
effective amount of a compound according to the invention for the treat-
ment of neoplastic growth, for example colon or breast carcinoma, is gen-
erally in the range from 0.1 to 100 mg/kg of body weight of the recipient
(mammal) per day and particularly typically in the range from 1 to 10 mg/kg
of body weight per day. Thus, the actual amount per day for an adult mam-
mal weighing 70 kg is usually between 70 and 700 mg, where this amount
can be administered as a single dose per day or usually in a series of part-
doses (such as, for example, two, three, four, five or six) per day, so that
the total daily dose is the same. An effective amount of a salt or solvate or
of a physiologically functional derivative thereof can be determined as the
fraction of the effective amount of the compound according to the invention
per se. It can be assumed that similar doses are suitable for the treatment
of other conditions mentioned above.
The invention furthermore relates to medicaments comprising at least one
compound of the formula la or lb and/or pharmaceutically usable salts and
stereoisomers thereof, including mixtures thereof in all ratios, and at least
one further medicament active ingredient.
CA 02784067 2012-06-12
WO 2011/0727'79
PCT/EP2010/006822
- 51 -
The invention also relates to a set (kit) consisting of separate packs of
(a) an effective amount of a compound of the formula la or lb and/or
pharmaceutically usable salts and stereoisomers thereof, including
mixtures thereof in all ratios,
and
(b) an effective amount of a further medicament active ingredient.
The set comprises suitable containers, such as boxes, individual bottles,
bags or ampoules. The set may, for example, comprise separate am-
poules, each containing an effective amount of a compound of the formula
la or lb and/or pharmaceutically usable salts and stereoisomers thereof,
including mixtures thereof in all ratios,
and an effective amount of a further medicament active ingredient in dis-
solved or lyophilised form.
USE
The present compounds are suitable as pharmaceutical active ingredients
for mammals, especially for humans, in the treatment of tyrosine kinase-
induced diseases. These diseases include the proliferation of tumour cells,
pathological neovascularisation (or angiogenesis) which promotes the
growth of solid tumours, ocular neovascularisation (diabetic retinopathy,
age-induced macular degeneration and the like) and inflammation (psoria-
sis, rheumatoid arthritis and the like).
The present invention encompasses the use of the compounds of the for-
mula la and lb and/or physiologically acceptable salts thereof for the
preparation of a medicament for the treatment or prevention of cancer.
Preferred carcinomas for the treatment originate from the group cerebral
carcinoma, urogenital tract carcinoma, carcinoma of the lymphatic system,
stomach carcinoma, laryngeal carcinoma and lung carcinoma. A further
group of preferred forms of cancer are monocytic leukaemia, lung adeno-
81565053
- 52 -
,
carcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastoMas
and breast carcinoma.
Also encompassed is the use of the compounds as described herein,
according to the invention and/or physiologically acceptable salts thereof
for the preparation of a medicament for the treatment or prevention of a
disease in which angiogenesis is implicated_
Such a disease in which angiogenesis is implicated is an ocular disease,
such as retinal vascularisation, diabetic retinopathy, age-induced macular
degeneration and the like.
The use of compounds of the formula la and lb and/or physiologically
acceptable salts and solvates thereof for the preparation of a medicament
for the treatment or prevention of inflammatory diseases also falls within
the scope of the present invention. Examples of such inflammatory dis-
eases include rheumatoid arthritis, psoriasis, contact dermatitis, delayed
hypersensitivity reaction and the like.
Also encompassed is the use of the compounds of the formula la and lb
and/or physiologically acceptable salts thereof for the preparation of a
medicament for the treatment or prevention of a tyrosine kinase-induced
disease or a tyrosine kinase-induced condition in a mammal, in which to
this method a therapeutically effective amount of a compound according to
the invention is administered to a sick mammal in need of such treatment.
The therapeutic amount varies according to the specific disease and can
be determined by the person skilled in the art without undue effort.
The present invention also encompasses the use compounds of the for-
mula la and lb and/or physiologically acceptable salts and solvates thereof
for the preparation of a medicament for the treatment or prevention of reti-
nal vascularisation.
Methods for the treatment or prevention of ocular diseases, such as dia-
betic retinopathy and age-induced macular degeneration, are likewise part
of the invention. The use for the treatment or prevention of inflammatory
diseases, such as rheumatoid arthritis, psoriasis, contact dermatitis and
CA 2784067 2017-08-03
81565053
- 53 -
delayed hypersensitivity reaction, as well as the treatment or prevention of
bone pathologies from the group osteosarcoma, osteoarthritis and rickets,
likewise falls within the scope of the present invention.
The expression "tyrosine kinase-induced diseases or conditions" refers to
pathological conditions that depend on the activity of one or more tyrosine
kinases. Tyrosine kinases either directly or indirectly participate in the sig-
nal transduction pathways of a variety of cellular activities, including
prolif-
eration,
roasdinheeksiionansaenadcmtivigityraitniocnluadnedpdroiffliefereranttioiantioon
f.tuDmisoeuarsceesilass, spoacthiaotieod
gi-
cal neovascularisation that promotes the growth of solid tumours, ocular
neovascularisation (diabetic retinopathy, age-induced macular degenera-
tion and the like) and inflammation (psoriasis, rheumatoid arthritis and the
like).
The compounds of the formula la and lb can be administered to patients
for the treatment of cancer, in particular fast-growing tumours.
The invention thus relates to the use of compounds of the formula la and
lb, and pharmaceutically usable salts and stereoisomers thereof, including
mixtures thereof in all ratios, for the preparation of a medicament for the
treatment of diseases in which the inhibition, regulation and/or modulation
of kinase signal transduction plays a role.
=
Preference is given to the use of compounds of the formula l, and pharma-
ceutically usable salts and stereoisomers thereof, including mixtures
thereof in all ratios,
for the preparation of a medicament for the treatment of diseases which
are influenced by inhibition of tyrosine kinases by the compounds as
described herein,
Particular preference is given to the use for the treatment of a disease
where the disease is a solid tumour.
CA 2784067 2017-08-03
CA 02784067 2012-06-12
WO 2011/072'779
PCT/EP2010/006822
- 54 -
The solid tumour is preferably selected from the group of tumours of the
lung, squamous epithelium, the bladder, the stomach, the kidneys, of head
and neck, the oesophagus, the cervix, the thyroid, the intestine, the liver,
the brain, the prostate, the urogenital tract, the lymphatic system, the
stomach and/or the larynx.
The solid tumour is furthermore preferably selected from the group lung
adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblas-
.
tomas, colon carcinoma and breast carcinoma.
Preference is furthermore given to the use for the treatment of a tumour of
the blood and immune system, preferably for the treatment of a tumour
selected from the group of acute myeloid leukaemia, chronic myeloid leu-
kaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.
The disclosed compounds of the formula la and lb can be administered in
combination with other known therapeutic agents, including anticancer
agents. As used here, the term "anticancer agent" relates to any agent
which is administered to a patient with cancer for the purposes of treating
the cancer.
The anti-cancer treatment defined herein may be applied as a sole therapy
or may involve, in addition to the compound of the invention, conventional
surgery or radiotherapy or chemotherapy. Such chemotherapy may include
one or more of the following categories of anti- tumour agents:
(i) antiproliferative/antineoplastic/DNA-damaging agents and
combi-
nations thereof, as used in medical oncology, such as alkylating agents
(for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard,
melphalan, chloroambucil, busulphan and nitrosoureas); antimetabolites
(for example antifolates such as fluoropyrimidines like 5-fluorouracil and
tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea and
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 55 -
gemcitabine); antitumour antibiotics (for example anthracyclines, like adria-
mycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mito-
mycin-C, dactinomycin and mithramycin) ; antimitotic agents (for example
vinca alkaloids, like vincristine, vinblastine, vindesine and vinorelbine, and
taxoids, like taxol and taxotere) ; topoisomerase inhibitors (for example
epipodophyllotoxins, like etoposide and teniposide, amsacrine, topotecan,
irinotecan and camptothecin) and cell-differentiating agents (for example
all-trans-retinoic acid, 13-cis-retinoic acid and fenretinide);
(ii) cytostatic agents, such as antioestrogens (for example tamoxifen,
toremifene, raloxifene, droloxifene and iodoxyfene), oestrogen receptor
downregulators (for example fulvestrant), antiandrogens (for example
bicalutannide, flutamide, nilutamide and cyproterone acetate), LHRH anta-
gonists or LHRH agonists (for example goserelin, leuprorelin and busere-
lin), progesterones (for example megestrol acetate), aromatase inhibitors
(for example as anastrozole, letrozole, vorazole and exemestane) and in-
hibitors of 50c-reductase, such as finasteride;
(iii) agents which inhibit cancer cell invasion (for example metallo-
proteinase inhibitors, like marimastat, and inhibitors of urokinase plasmi-
nogen activator receptor function);
(iv) inhibitors of growth factor function, for example such inhibitors in-
clude growth factor antibodies, growth factor receptor antibodies (for ex-
ample the anti-erbb2 antibody trastuzumab [HerceptinTM] and the anti-
erbb1 antibody cetuximab [C225]), farnesyl transferase inhibitors, tyrosine
kinase inhibitors and serine/threonine kinase inhibitors, for example inhibi-
tors of the epidermal growth factor family (for example EGFR family
tyrosine kinase inhibitors, such as N-(3-chloro-4-fluoropheny1)-7-methoxy-
6- (3-morpholinopropoxy) quinazolin-4-amine (gefitinib, AZD-1839), N-(3-
ethynylpheny1)-6,7-bis (2-methoxyethoxy)quinazolin-4-amine (erlotinib,
OS1-774) and 6-acrylamido-N-(3-chloro-4-fluorophenyI)-7-(3-morpholino-
propoxy)quinazolin-4-amine (Cl 1033) ), for example inhibitors of the
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 56 -
platelet-derived growth factor family and for example inhibitors of the
hepatocyte growth factor family;
(v)antiangiogenic agents, such as those which inhibit the effects of vascu-
lar endothelial growth factor, (for example the anti-vascular endothelial cell
growth factor antibody bevacizumab [AvastinTm], compounds such as
those disclosed in published international patent applications
WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and
compounds that work by other mechanisms (for example linomide, inhibi-
tors of integrin avp3 function and angiostatin);
(vi) vessel-damaging agents, such as combretastatin A4 and com-
pounds disclosed in international patent applications WO 99/02166,
WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and
WO 02/08213;
(vii) antisense therapies, for example those which are directed to the
targets listed above, such as ISIS-2503, an anti-Ras antisense;
(viii) gene therapy approaches, including, for example, approaches for
replacement of aberrant genes, such as aberrant p53 or aberrant BRCA1
or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches,
such as those using cytosine deaminase, thymidine kinase or a bacterial
nitroreductase enzyme, and approaches for increasing patient tolerance to
chemotherapy or radiotherapy, such as multi-drug resistance gene ther-
apy; and
(ix) innmunotherapy approaches, including, for example, ex-vivo and
in-vivo approaches for increasing the immunogenicity of patient tumour
cells, such as transfection with cytokines, such as interleukin 2, interleukin
4 or granulocyte-macrophage colony stimulating factor, approaches for
decreasing T-cell anergy, approaches using transfected immune cells,
such as cytokine-transfected dendritic cells, approaches using cytokine-
transfected tumour cell lines, and approaches using anti-idiotypic anti-
bodies.
CA 02784067 2012-06-12
WO 2011/0'72779 PCT/EP2010/006822
- 57 -
The medicaments from Table 1 below are preferably, but not exclusively,
combined with the compounds of the formula I.
Table 1.
Alkylating agents Cyclophosphamide Lomustine
Busulfan Procarbazine
Ifosfamide Altretamine
Melphalan Estramustine phosphate
Hexamethylmelamine Mechloroethamine
Thiotepa
Streptozocin
Chloroambucil
Temozolomide
Dacarbazine
Carmustine Semustine
Platinum agents Cisplatin Carboplatin
Oxaliplatin ZD-0473 (AnorMED)
Spiroplatin Lobaplatin (Aetema)
Carboxyphthalatoplatinurn Satraplatin (Johnson
Tetraplatin Matthey)
Ormiplatin
BBR-3464 (Hoffmann-La
Iproplatin
Roche)
SM-11355 (Sumitomo)
AP-5280 (Access)
Antimetabolites Azacytidine Tomudex
Gemcitabine Trimetrexate
Capecitabine Deoxycoformycin
5-Fluorouracil Fludarabine
Floxuridine Pentostatin
2-Chlorodesoxyadenosine Raltitrexed
6-Mercaptopurine
6-Thioguanine Hydroxyurea
Cytarabine Decitabine (SuperGen)
2-Fluorodesoxycytidine Clofarabine (Bioenvision)
Methotrexate Irofulven (MGI Pharrna)
ldatrexate DMDC (Hoffmann-
La Roche)
Ethynylcytidine (Taiho )
Topoisomerase Amsacrine Rubitecan (SuperGen)
inhibitors Epirubicin Exatecan mesylate (Dalichi)
Etoposide Quinamed (ChemGenex)
Teniposide or mitoxantrone Gimatecan (Sigma- Tau)
Irinotecan (CPT-11) Diflomotecan (Beaufour-
,
7-Ethyl-10-hydroxy- lpsen)
camptothecin
TAS-103 (Taiho)
Topotecan
Elsamitrucin (Spectrum)
Dexrazoxanet TosoTars et
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 58 -
Pixantrone (Novuspharrna) J-107088 (Merck & Co) I
Rebeccamycin analogue BNP-1350 (BioNumerik)
(Exelixis) CKD-602 (Chong Kun
BBR-3576 (Novuspharrna) Pang)
KW-2170 (Kyowa Hakko)
Antitumour Dactinomycin (Actinomycin D) Amonafide
antibiotics Doxorubicin (Adriamycin) Azonafide
Deoxyrubicin Anthrapyrazole
Valrubicin Oxantrazole
Daunorubicin (Daunomycin) Losoxantrone
Epirubicin
Bleomycin sulfate
Therarubicin
(
ldarubicin Blenoxan)
Rubidazon Bleomycinic acid
PlicamycinpBleomycin A
Porfiromycin Bleomycin B
Cyanomorpholinodoxorubicin Mitomycin C
Mitoxantron (Novantron) MEN-10755 (Menarini)
GPX-100 (Gem
Pharmaceuticals)
Antinnitotic agents Paclitaxel SB 408075
Docetaxel (GlaxoSmithKline)
Colchicine E7010 (Abbott)
Vinblastine PG-TXL (Cell Therapeutics)
Vincristine IDN 5109 (Bayer)
Vinorelbine
A 105972 (Abbott)
Vindesine
A 204197 (Abbott)
Dolastatin 10 (NCI)
Rhizoxin (Fujisawa) LU 223651 (BASF)
Mivobulin (Warner-Lambert) D 24851 (ASTA Medica)
Cemadotin (BASF) ER-86526 (Eisai)
RPR 109881A (Aventis) Combretastatin A4 (BMS)
TXD 258 (Aventis) lsohomohalichondrin-B
Epothilone B (Novartis) (PharmaMar)
T 900607 (Tularik) ZD 6126 (AstraZeneca)
T 138067 (Tularik) PEG-Paclitaxel (Enzon)
Cryptophycin 52 (Eli Lilly) AZ10992 (Asahi)
Vinflunine (Fabre) !DN-5109 (lndena)
Auristatin PE (Teikoku
AVLB (Prescient
Hormone)
NeuroPharma)
BMS 247550 (BMS)
BMS 184476 (BMS) Azaepothilon B (BMS)
BMS 188797 (BMS) BNP- 7787 (BioNumerik)
Taxoprexin (Protarga) CA-4-prodrug (OXiGENE)
Dolastatin-10 (NrH)
CA-4 (OXiGENE)
Aromatase Aminoglutethimide Exemestan
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 59 -
inhibitors Letrozole Atamestan
(BioMedicines)
Anastrazole YM-511 (Yamanouchi)
_____________________________ Formestan
Thymidylate Pemetrexed (Eli Lilly) Nolatrexed (Eximias)
synthase inhibitors ZD-9331 (BTG) CoFactor TM (BioKeys)
DNA antagonists Trabectedin (PharmaMar) Mafosfamide (Baxter
Glufosfamide (Baxter International)
International) Apaziquone (Spectrum
Albumin + 32P (Isotope Pharmaceuticals)
Solutions)06-benzylguanine
Thymectacin (NewBiotics)
(Pali gent)
Edotreotid (Novartis) _____________________________________________________
= Farnesyl transferase Arglabin (NuOncology Labs) Tipifarnib (Johnson &
= inhibitors lonafarnib (Schering-Plough)
Johnson)
BAY-43-9006 (Bayer) Perillyl alcohol (DOR
BioPharma)
Pump inhibitors CBT-1 (CBA Pharnna) Zosuquidar
trihydrochloride
Tariquidar (Xenova) (Eli Lilly)
MS-209 (Schering AG) Biricodar dicitrate
(Vertex)
Histone acetyl trans- Tacedinaline (Pfizer) Pivaloyloxymethyl
butyrate
ferase inhibitors SAHA (Aton Pharma) (Titan)
MS-275 (Schering AG) Depsipeptide (Fujisawa)
Metalloproteinase Neovastat (Aeterna CMT -3 (CollaGenex)
inhibitors Laboratories) BMS-275291 (Celltech)
Ribonucleoside Marimastat (British Biotech) Tezacitabine
(Aventis)
reductase inhibitors Gallium maltolate (Titan) Didox (Molecules for
Triapin (Vion) Health)
TNF-alpha Virulizin (Lorus Therapeutics) Revimid
(Celgene)
agonists / anta- CDC-394 (Celgene)
_gonists
Endothelin-A Atrasentan (Abbot) YM-598 (Yamanouchi)
receptor ZD-4054 (AstraZeneca)
antagonists
Retinoic acid recepto Fenretinide (Johnson & Johns( Alitretinoin (Ligand)
agonists LGD-1550 (lig_and)
Immunomodulators Interferon Dexosome therapy (Anosys
Oncophage (Antigenics) Pentrix (Australian C
GMK (Progenics) ancer
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 60 -
Adenocarcinoma vaccine Technology)
(Biomira) JSF-154 (Tragen)
CTP-37 (AVI BioPharma) Cancer vaccine (Intercell)
JRX-2 (Immuno-Rx) Norelin (Biostar)
PEP-005 (Peplin Biotech) BLP-25 (Biomira)
Synchrovax vaccines (CTL
Immuno) MGV (Progenics)
!
Melanoma vaccine (CTL 3-Alethin (Dovetail)
lmmuno) CLL-Thera (Vasogen)
p21-RAS vaccine (GemVax)
Hormonal and Oestrogens Prednisone
antihormonal Conjugated oestrogens Methylprednisolone
agents Ethynyloestradiol Prednisolone
Chlorotrianisene Aminoglutethimide
ldenestrol Leuprolide
Hydroxyprogesterone caproate Goserelin
Medroxyprogesterone
Testosterone Leuporelin
Testosterone propionate Bicalutamide
Fluoxymesterone Flutamide
Methyltestosterone Octreotide
Diethylstilbestrol Nilutamide
Megestrol Mitotan
Tamoxifen P-04 (Novogen)
Toremofin 2-Methoxyoestradiol
Dexamethasone (EntreMed)
Arzoxifen (Eli Lilly)
Photodynamic Talaporfin (Light Sciences) Pd-Bacteriopheophorbid
agents Theralux (Theratechnologies) (Yeda)
Motexafin-Gadolinium Lutetium-Texaphyrin
(Pharmacyclics) (Pharmacyclics)
Hypericin
Tyrosine kinase Imatinib (Novartis) Kahalide F (PharmaMar)
inhibitors Leflunomide(Sugen/Pharmaci CEP- 701 (Cephalon)
ZDI839 (AstraZeneca) CEP-751 (Cephalon)
Erlotinib (Oncogene Science) MLN518 (Millenium)
Canertjnib (Pfizer) PKC412 (Novartis)
Squalamine (Genaera)
Phenoxodiol
SU5416 (Pharmacia)
SU6668 (Pharmacia) Trastuzumab (Genentech)
ZD4190 (AstraZeneca) 0225 (ImClone)
ZD6474 (AstraZeneca) rhu-Mab (Genentech)
Vatalanib (Novartis) MDX-H210 (Medarex)
PKI166 (Novartis) 2C4 (Genentech)
GW2016 (GlaxoSmithKline) MDX-447 (Medarex)
EKB-509 (Wyeth) ABX-EGF (Abgenix)
EKB-569 (Wyeth) IMC-1C11 (ImClone)
CA 02784067 2012-06-12
,
WO 2011/072779 PCT/EP2010/006822
- 61 -
Various agents SR-27897 (CCK-A inhibitor, BCX-1777 (PNP inhibitor,
Sanofi-Synthelabo) BioCryst)
Tocladesine (cyclic AMP Ranpirnase (ribonuclease
agonist, Ribapharm) stimulant, Alfacell)
Alvocidib (CDK inhibitor, Avent Galarubicin (RNA
CV-247 (COX-2 inhibitor, Ivy
Medical) synthesis inhibitor, Dong-A)
P54 (COX-2 inhibitor, Tirapazamine
Phytopharm) (reducing agent, SRI
CapCell TM (CYP450 stimulant, International)
Bavarian Nordic) N-Acetylcysteine
GCS-I00 (gal3 antagonist, (reducing agent, Zambon)
GlycoGenesys) R-Flurbiprofen (NF-kappaB
G17DT immunogen (gastrin inhibitor, Encore)
inhibitor, Aphton) 3CPA (NF-kappaB inhibitor,
Efaproxiral (oxygenator, Allos Active Biotech)
Therapeutics) Seocalcitol (vitamin D
PI-88 (heparanase inhibitor, receptor agonist, Leo)
Progen)
131-I-TM-601 (DNA
Tesmilifen (histamine
antagonist, YM BioSciences) antagonist, Trans
Histamine (histamine H2 Molecular)
receptor agonist, Maxim) Eflornithin (ODC inhibitor,
Tiazofurin (IMPDH inhibitor, ILEX Oncology)
Ribapharm) Minodronic acid
Cilengitide (integrin antagonist (osteoclast inhibitor,
Merck KGaA) Yamanouchi)
SR-31747 (IL-1 antagonist, Indisulam (p53 stimulant,
Sanofi-Synthelabo) Eisai)
CCI-779 (mTOR kinase Aplidin (PPT inhibitor,
inhibitor, Wyeth) PharmaMar)
Exisulind (PDE-V inhibitor,
Rituximab (CD20 antibody,
Cell Pathways)
Genentech)
CP-461 (PDE-V inhibitor, Cell
Pathways) Gemtuzumab (CD33
AG-2037 (GART inhibitor, antibody, VVyeth Ayerst)
Pfizer) PG2 (haematopoiesis
V\OC-UK1 (plasminogen promoter, Pharmagenesis)
activator inhibitor, VVilex) Immunol TM (triclosan
PBI-1402 (PMN stimulant, mouthwash, Endo)
ProMetic LifeSciences) Triacetyluridine (uridine
Bortezomib (proteasome inhibi prodrug, Wellstat)
Millennium) SN-4071 (sarcoma agent,
SRL-172 (T-cell stimulant, SR Signature BioScience)
Pharma)
TransMID-107Tm
TLK-286 (glutathione-S
transferase inhibitor, Telik) (immunotoxin, KS
PT-100 (growth factor Biomedix)
agonist, Point Therapeutics) PCK-3145 (apoptosis
Midostaurin (PKC inhibitor, promoter, Procyon)
I Novartis) Doranidazole (apoptosis
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 62 -
Bryostatin-1 (PKC stimulant, promoter, Pola)
GPC Biotech) CHS-828 (cytotoxic agent,
CDA-11(apoptosis promoter, Leo)
Everlife) trans-Retinic acid
SDX-101 (apoptosis promoter, (differentiator, NIH)
cSalmiaetodnixin
ef
(apoptosis promote! MX6 (apoptosis promoter,
ChemGenex) MAXIA)
Apomine (apoptosis
promoter, ILEX Oncology)
Urocidin (apoptosis promot:
Bioniche)
Ro-31-7453 (apoptosis
promoter, La Roche)
Brostallicin (apoptosis
oromoter, Pharmacia
A combined treatment of this type can be achieved with the aid of simulta-
neous, consecutive or separate dispensing of the individual components of
the treatment. Combination products of this type employ the compounds
according to the invention.
ASSAYS
The compounds of the formula la and lb described in the examples were
tested by the assays described below and were found to have kinase in-
hibitory activity. Other assays are known from the literature and could
readily be performed by the person skilled in the art (see, for example,
Dhanabal et al. Cancer Res.1999; 59: 189 - 97; Xin et al. J. Biol.
Chem.1999 ; 274: 9116 - 21; Sheu et al. Anticancer Res.1998 ; 18: 4435 -
41; Ausprunk et al. Dev. Bio1.1974; 38: 237 - 48; Gimbrone et al. J. Natl.
Cancer Inst. 1974; 52: 413 - 27; Nicosia et al. In Vitro 1982; 18: 538 - 49).
Filter binding assay
The substances are tested in accordance with the following provisions:
81565053
- 63 -
All equipment, solvents, buffers and enzymes used are commercially avail-
able.
TM
All kinase assays were carried out using the Multidrop 384 from Thermo-
Fisher at room temperature in a total assay volume of 25.5 pl. 15 pl of an
enzyme mix comprising enzyme and substrate in buffer are added to the test
batch comprising either 0.5 pl of test substance, DMSO control or empty con-
tainer. Test substances are pre-incubated in the presence of the enzyme and
ATp substrate(co for c eor s
(concentration kinase
-dependent
reaction initiatedor 5 0 mbmy ).addition.rh e re reaction
i1o0n pi is
of
t5raminn kut
ter-
minated by addition of 5 pl of orthophosphoric acid (50 mM). The test contain-
ers are then transferred onto P81 Unifilterplates by means of a "Packard Har-
TM TM
vester" and dried in air. The dry Unifilter plates are sealed after the
addition of
TM TM
MicroScint 0, and the radioactivity is determined in a Packard Topcount NXT.
Assay of NUAK1 inhibition
NUAK1 (5-20 mU diluted in 50 mM Tris pH 7.5, 0.1 mM EGTA, 0.1%
6-mercaptoethanol, 1mg/m1 of BSA) is tested against ALNRTSSDSALHRRR
as substrate. The final volume of 25.5 pl contains 50 mM Tris pH 7.5, 0.1 mM
EGTA, 0.3 mM ALNRTSSDSALHRRR, 10 mM magnesium acetate and 0.02
mM [33P-y-ATP] (50-1000 cpm/pmole) and is incubated at room temperature
for 30 min. Tests are terminated by the addition of 5 pl of a 0.5 M (3%) ortho-
phosphoric acid soln. and then transferred onto P81 Unifilte-Pplates and
washed with 50 mM orthophosphoric acid buffer.
Measurement of Met kinase activity
According to the manufacturer's data (Met, active, upstate, catalogue No.
14-526), Met kinase is expressed for the purposes of protein production in
insect cells (Sf21; S. frugiperda) and subsequent affinity-chromatographic
purification as "N-terminal 6His-tagged" recombinant human protein in a
baculovirus expression vector.
CA 2784067 2017-08-03
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 64 -
The kinase activity can be measured using various available measurement
systems. In the scintillation proximity method (Sorg et al., J. of Biomolecu-
lar Screening, 2002, 7, 11-19), the flashplate method or the filter binding
test, the radioactive phosphorylation of a protein or peptide as substrate is
measured using radioactively labelled ATP (32P-ATP, 33P-ATP). In the
case of the presence of an inhibitory compound, a reduced radioactive
signal, or none at all, can be detected. Furthermore, homogeneous time-
resolved fluorescence resonance energy transfer (HTR-FRET) and fluores-
cence polarisation (FP) technologies can be used as assay methods (Sills
et al., J. Biomol. Screen. 2002; 7 (3): 191 - 214).
Other non-radioactive ELISA assay methods use specific phospho-anti-
bodies (phospho-ABS). The phospho-antibody only binds the phosphor-
ylated substrate. This binding can be detected by chemiluminescence
using a second peroxidase-conjugated antibody (Ross et al. Biochem. J.
2002, 366: 977 - 981).
Flashplate method (Met kinase)
The test plates used are 96-well FlashplateR microtitre plates from Perkin
Elmer (Cat. No. SMP200). The components of the kinase reaction
described below are pipetted into the assay plate. The Met kinase and the
substrate poly Ala-Glu-Lys-Tyr, (pAGLT, 6:2:5:1), are incubated for 3 hrs at
room temperature with radioactively labelled 33P-ATP in the presence and
absence of test substances in a total volume of 100 pl. The reaction is
terminated using 150 pl of a 60 mM EDTA solution. After incubation for a
further 30 min at room temperature, the supernatants are filtered off with
suction, and the wells are washed three times with 200 pl of 0.9% NaCI
solution each time. The measurement of the bound radioactivity is carried
out by means of a scintillation measuring instrument (Topcount NXT,
Perkin-Elmer).
81565053
- 65 -
The full value used is the inhibitor-free kinase reaction. This should be ap-
proximately in the range 6000-9000 cpm. The pharmacological zero value
used is staurosporin in a final concentration of 0.1 mM. The inhibitory val-
ues (IC50) are determined using the RS1_MTS program.
Kinase reaction conditions per well:
30 pl of assay buffer
1 100 pp oo ff As uTbps t(af inn cael ct oo nbcee tnet rsat ed i n
t o n1 assaypm cold,
obl du,f bufferwith 1 0%ci 0f33o D
33P-ATP) -AM0
T PS)
50 pl of Met kinase/substrate mixture in assay buffer;
(10 ng of enzyme/well, 50 ng of pAGLT/well)
Solutions used:
- Assay buffer:
50 mM HEPES
3 mM magnesium chloride
3 pM sodium orthovanadate
3 mM manganese(II) chloride
1 mM dithiothreitol (DTT)
pH = 7.5 (to be set using sodium hydroxide)
- Stop solution:
TM
60 mM Titriplex III (EDTA)
- 33P-ATP: Perkin-Elmer;
- Met kinase: Upstate, Cat. No. 14-526, stock 1 pg/10 pl; spec. activity
954 U/mg;
- Paly-Ala-Glu-Lys-Tyr, 6 : 2 : 5: 1 : Sigma Cat. No. P1152
In-vivo tests
Experimental procedure: Female Balb/C mice (breeder: Charles River
Wiga) were 5 weeks old on arrival. They were acclimatised to our keeping
CA 2784067 2017-08-03
81565053
- 66 -
conditions for 7 days. Each mouse was subsequently injected subcutane-
ously in the pelvic area with 4 million TPR-Met/NIH3T3 cells in 100 pl of
PBS (without Ca++ and Mg++). After 5 days, the animals were randomised
into 3 groups, so that each group of 9 mice had an average tumour volume
of 110 pl (range: 55 ¨ 165). 100 pl of vehicle (0.25% methylcellulose/
100 mM acetate buffer, pH 5.5) were administered daily to the control
group, and 200 mg/kg of "A56'' or "A91" dissolved in the vehicle (volume
likewise 100 pl/animal) were administered daily to the treatment groups, in
each case by gastric tube. After 9 days, the controls had an average vol-
ume of 1530 pl and the experiment was terminated.
Measurement of the tumour volume: The length (L) and breadth (B) were
TM
measured using a Vernier calliper, and the tumour volume was calculated
from the formula LxBx B/2.
Keeping conditions: 4 or 5 animals per cage, feeding with commercial
mouse food (Sniff).
Conditions for the HPLC-based analytical methods:
TM
ESI-MS: Agilent 1200 Binary Pump
Solvent A: water/0.05% of formic acid
Solvent B: ACN/0.04 /0 of formic acid
Minimun pressure limit (bar): 0.0; Maximum pressure limit (bar): 200.0;
Post run time (min): 0.00;
Gradient program: Time Flow Rate Composition
0.00(min) 2.40(ml/min) A=96.0% B=4.0% gradient to
2.80(min) 2.40 (ml/min) A=0.0% B=100.0%
3.30(min) 2.40 (ml/min) A=0.0% B=100.0% gradient to
3.40(min) 2.40 (ml/min) A=96.0% B=4.0%
Column: ChromolitTliPerformance Speed ROD RP18e/50-4.6nm
CA 2784067 2017-08-03
81565053
- 67 -
Autosampler: Agilent 1200 ALS G1329A
Pump: Agilent 1200 BinPump G1312A, Degasser: Agilent 1200 G1379B
Detector: Agilent 1200 VWL G1314B
MS: Agilent 6110 Quadrupole LC/MS
ESI interface G1946-60450, positive ionisation (or negative ionisation as
indicated below), Injection volume: 10 pl
ESI-HRMS: Agilent 1100 Binary Pump
Solvent A: water/0.1 A of FAc
Solvent B: ACN/0.1 % of FAc
Minimun pressure limit (bar): 0.0; Maximum pressure limit (bar): 400.0;
Post run time (min): 0.00
Gradient program: Time Flow Rate Composition
0.00(min) 0.50(ml/min) A=98.0% B=2.0%
5.00(min) 0.50(ml/min) A=2.0% 6=98.0%
8.00(min) 0.50(ml/min) A=2.0% B=98.0%
8.10(min) 6.50(ml/min) A=98.0% B=2.0%
13.00(min) 0.50(ml/min) A=98.0 /0 B=2.0%
TM
Column: 135 - Purospher Star RP-18e (3pm), 55-2, Art. 1.50241, No.
242994
Autosampler: Agilent 1100 ALS G1329A
pump: Agilent 1100 BinPump G1312A
Column oven: Agilent 1100 Column Oven G1316A
Detection: Agilent 1100 DAD G1315B
MS: Thermo LTQ XL Orbitra-prm
ESI interface
positive ionisation
Injection volume: 5 ¨ 20 ul
APCI-MS:
Solvent A:water + 0.1%of HCOOH
CA 2784067 2017-08-03
81565053
- 68 -
Solvent B:acetonitrile + 0.1% of HCOOH
Solvent C:C
Solvent D:D
Min pressure (bar):0
Max pressure (bar):300
Delay volume (m1):0.00
Equilibration time (min):0.00
Gradient curve: linear
Gradient program:
Time(min) Flow(ml/min) A(%) B(%) C(%) D(%)
0.00 0.50 98 2 0 0
5.00 0.50 2 98 0 0
8.00 0.50 2 98 0 0
8.10 0.50 98 2 0 0
13.00 0.50 98 2 0 0
Column: Purosphere RP-18, 55-2, Art. 1.50241.0001, batch: 641047
Pump: FinnigarnmSpectra P4000 system
Detection: FinnigaTii UV6000LP
MS: FinnigaTrimLCQ Deca
APCI interface, Positive ionisation
Inj. vol.: 10 pl
Agilent
Column: Chromolite Performance RP18-e 50-4.6mm
A: acetonitrile comprising 0.05% of formic acid
B:H20 comprising 0.05% of formic acid
Flow rate: 2.4m1/min
Method:
Time [min] %of B
0 4
CA 2784067 2017-08-03
81565053
-69-
2.8 100
3.3 100
3.4 4 =
Agilent
Column:
XBridglemC8 (50x4.6 mm, 3.5 u), +ve mode
Method:
A: 0.1% of TFA in H20
B: 0.1% of TFA in acetonitrile
Flow rate: 2.0 ml/min
Gradient:
Time [min] %of B
0 5
8.0 100
8.1 100
8.5 5
10 5
Above and below, all temperatures are indicated in C. In the following ex-
amples, "conventional work-up" means: water is added if necessary,.the
pH is adjusted, if necessary, to values between 2 and 10, depending on
the constitution of the end product, the mixture is extracted with ethyl ace-
tate or dichloromethane, the phases are separated, the organic phase is
dried over sodium sulfate and evaporated, and the residue is purified by
chromatography on silica gel and/or by crystallisation. Rf values on silica
gel; eluent: ethyl acetate/methanol 9:1;
Mass spectrometry (MS): El (electron impact ionisation) M+
FAB (fast atom bombardment) (M+H)*
ESI (electrospray ionisation) (M+H)+
=
CA 2784067 2017-08-03
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 70 -
APCI-MS (atmospheric pressure chemical ionisation - mass spectrometry)
(M+H)*;
melting point m.p. in C.
Example 1
Preparation of 6-benzy1-4H-pyrrolo[2,3-d]thiazole ("A7")
HN
1.1
N S
1.1 tert-Butyl N-(1,3-thiazol-4-yl)carbamate (''1")
0
N 0
5.80 ml (41.84 mmol) of triethylamine and subsequently, with ice-bath cooling,
9.10 ml (42.19 mmol) of diphenyl azidophosphate are introduced into a solu-
tion of 4.85 g (37.55 mmol) of 4-thiazolecarboxylic acid in 180 ml of tert-
butanol under nitrogen, and the reaction mixture is heated under reflux for
16 h. The solvent is removed in vacuo, the residue is taken up in dichloro-
methane and washed twice with water and saturated NaCI solution. The
organic phase is dried over sodium sulfate, evaporated in vacuo, and the resi-
due is purified by chromatography on silica gel (eluent: cyclohexane/ethyl
acetate 1/1), giving 7.07 g (35.30 mmol, 94%) of tert-butyl N-(1,3-thiazol-4-
yl)carbamate as beige crystals; ESI-MS: m/e: 201 (1M+H]+).
1.2 tert-Butyl N-(5-iodo-1,3-thiazol-4-yl)carbamate ("2")
/---==N 0
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 71 -
1033 mg (4.59 mmol) of N-iodosuccinimide are introduced into a solution of
800 mg (3.99 mmol) of tert-butyl N-(1,3-thiazol-4-yl)carbamate in 40 ml of
dichloroethane, and the reaction mixture is heated under reflux for 2h. After
cooling, the mixture is washed twice with water and with saturated sodium
thiosulfate solution. The combined organic phases are dried over sodium sul-
fate, evaporated in vacuo, and the residue is purified by flash chromatography
on silica gel (eluent: cyclohexane / ethyl acetate 8/2 to 1/1), giving 1.19 g
(3.43 mmol, 85%) of tert-butyl N-(5-iodo-1,3-thiazol-4-yl)carbamate as white
crystals after crystallisation from diethyl ether; ESI-MS: m/e: 327 ([M+H]+).
1.3 652 mg (2.00 mmol) of tert-butyl N-(5-iodo-1,3-thiazol-4-
yl)carbamate
and 2.6 g (8.00 mmol) of caesium carbonate are dissolved in 10 ml of dry
DMF in a dried Schlenk flask under nitrogen, and 622 mg (3.00 mmol) of cin-
namyl bromide are added. After stirring at room temperature for 2 h and posi-
tive reaction monitoring by means of thin-layer chromatography, 22 mg
(0.10 mmol) of Pd(OAc)2 and 52 mg (0.20 mmol) of PPh3 are introduced, and
the reaction mixture is stirred at 100 C for 19 h. Saturated NaCI solution is
then added to the reaction mixture, which is then extracted with ethyl
acetate.
The combined organic phases are dried over sodium sulfate, evaporated in
vacuo together with about three times the amount of Si02 and heated at
100 C and about 10 mbar for 5 h. The substrate/silica gel mixture is subse-
quently purified directly by chromatography on a silica-gel column (eluent:
cyclohexane/ethyl acetate 1/1), giving 214 mg (0.99 mmol, 49%) of 6-benzy1-
4H-pyrrolo[2,3-d]thiazole as yellow residue;
m.p. 133-135;
APCI-MS: Rt: 3.90 min; m/e (%): 215 (100, [M-1-H]);
1H NMR (400 MHz, DMSO-d6): 6 [ppm] 3.90 (s, 2H), 7.01 (dd, JH,H = 2.3
Hz, JH,H =1.3 Hz, 1H), 7.14-7.34 (m, 5H), 8.65 (d, JH,H =-1.3 Hz, 1H), 11.58
(s, 1H);
13C NMR (100 MHz, DMSO-d6): 6 [ppm] 32.14, 111.80, 113.02, 119.80,
125.42, 127.78, 127.96, 140.00, 149.75, 151.27.
=
81565053
- 72 -
Example 2
Preparation of tert-butyl N4542-(4-fluorophenyl)ethyny1]-1,3-thiazol-4-
yl}carbamate ("A15")
= 10
0NH
=
N N
LS
2.93 g (9 mmol) of caesium carbonate are dried in an evacuated Schlenk flask
under temperature, and 50 ml of dry tetrahydrofuran, 978 mg (3.00 mmol) of
tert-butyl N-(5-iodo-1,3-thiazol-4-yl)carbamate, 396 mg (3.30 mmol) of 1-
ethyny1-4-fluorobenzene, 122 mg (0.15 mmol) of Pd(dppf)2C12-CH2C12 and
57 mg (0.30 mmol) of Cul are subsequently added under nitrogen. The reac-
tion mixture is heated at 50 C for 6 h, subsequently cooled and filtered
through CelitTem, and the solvent is removed in vacuo. The residue is taken up
with ethyl acetate and washed with saturated NaCl solution. The combined
organic phases are dried over sodium sulfate, evaporated in vacuo, and the
residue is purified by chromatography on silica gel (eluent: cyclohexane/ethyl
acetate 1/1), giving 820 mg (2.57 mmol, 85%) of tert-butyl N-{542-(4-fluoro-
phenyl)ethyny11-1,3-thiazol-4-yl}carbamate as yellow solid from diethyl ether;
m.p. 139-144;
1H NMR (400 MHz, DMSO-d6): 6 [ppm] 1.45 (s, 9H), 7.22 ¨ 7.39 (m, 2H),
7.50 ¨ 7.68 (m, 2H), 8.98 (s, 1H), 9.62 (s, 1H);
13C NMR (100 MHz, DMSO-d6): 6 [ppm] 27.43, 78.84, 96.31, 105.54,
115.35 (d, 2Jc,F = 22 Hz), 117.92, 117.95, 132.88 (d, 3Jc,F = 8 Hz), 150.65,
151.83, 152.1, 161.63 (d, 1Jc,F = 246 Hz);
ESI-MS: Rt: 2.47 min; m/e (%): 319 (100, [M+H]).
CA 2784067 2017-08-03
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 73 -
Example 3
Preparation of tert-butyl N-{2-chloro-542-(4-fluorophenypethyny1]-1,3-thia-
zol-4-yllcarbamate ("A29a")
=ON F
N"
CI
2.63 g (8.26 mmol) of tert-butyl N-{542-(4-fluorophenyl)ethyny1]-1,3-thiazol-4-
yl}carbamate are dissolved in 100 ml of dry THF in a dried Schlenk flask under
nitrogen and cooled to -78 C. 11 ml of a 15% solution of n-BuLi in n-hexane
are then slowly added dropwise, and the mixture is stirred at -78 C for 20
min.
1120 mg (8.38 mmol) of N-chlorosuccinimide dissolved in 1 ml of dry THF are
subsequently added dropwise, and the mixture is stirred at -78 C for 15 min,
then quenched using 10 ml of n-butanol and warmed to RT. The solvent is
removed in vacuo, and the residue is purified directly by chromatography on
silica gel (eluent: cyclohexane/ethyl acetate 99/1), giving 2.3 g (6.51 mmol,
78%) of tert-butyl N-{2-chloro-542-(4-fluorophenyl)ethyny11-1,3-thiazol-4-yll-
carbamate as beige solid from PE; ESI-MS: m/e: 353 ([M+H]).
30
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 74 -
Example 4
Preparation of tert-butyl N-R-(2-aminopyrimidin-5-y1)-512-(4-fluoropheny1)-
ethynyll-1,3-thiazol-4-yl]carbamate ("A29")
H
\ 0
N N
10S
H2N
705 mg (2.00 mmol) of tert-butyl N-(2-chloro-542-(4-fluorophenypethyny1]-1,3-
thiazol-4-yl}carbamate are dissolved in a mixture of 4 ml of DMF, 2 ml of
water
and 8 ml of DME together with 663 mg (3.00 mmol) of pinacolyl 2-amino-
pyrimidine-5-boronate, and 829 mg (6.00 mmol) of potassium carbonate and
81 mg (0.10 mmol) of Pd(dppf)2C12-CH2C12 are introduced. Argon is subse-
quently passed through the reaction mixture for 10 min, the vessel is sealed
and heated at 85 C for 44 h. After cooling, the reaction mixture is extracted
twice with saturated NaCI solution, and the aqueous phases are extracted with
ethyl acetate. The combined organic phases are dried over sodium sulfate,
evaporated in vacuo, and the residue is purified by flash chromatography on
silica gel (eluent: cyclohexane/ethyl acetate 1/2: 1% of triethylamine),
giving
205 mg (0.49 mmol, 25%) of tert-butyl N42-(2-aminopyrimidin-5-y1)-542-(4-
fluorophenyl)ethyny1]-1,3-thiazol-4-yl]carbamate as yellow solid; m.p. 201-
203;
1H NMR (300 MHz, DMSO-d6): 6 [ppm] 1.46 (s, 9H), 7.23 ¨ 7.49 (m, 4H),
7.51 ¨ 7.70 (m, 2H), 8.72 (s, 2H), 9.63 (s, 1H);
ESI-MS: Rt: 2.43 min; m/e (c/o): 412 (100, [M+H]+), 356 (60, [M-tBu+2H]+).
CA 02784067 2012-06-12
WO 2011/072779 PCT/E P2010/006822
- 75 -
Example 5
Preparation of 5-(4-fluoropheny1)-4H-pyrrolo[2,3-4-1,3-thiazole ("Al")
<"N,N (¨
F
238 mg (0.75 mmol) of tert-butyl N-{512-(4-fluorophenypethyny1]-1,3-thiazol-4-
yllcarbamate are dissolved in 4.5 ml of NMP in a microwave vessel, and
143 mg (1.27 mmol) of KOtBu are added. The reaction vessel is sealed under
nitrogen and heated at 90 C for 20 min in the microwave while cooling in a
stream of nitrogen. The mixture is diluted with 50 ml of diethyl ether and
washed with 50 ml of sat. NaCI solution. The aqueous phase is again extrac-
ted with diethyl ether. The combined organic phases are dried over sodium
sulfate, evaporated in vacuo, and the residue is purified by chromatography
on silica gel (eluent: cyclohexane/ethyl acetate 1/1), giving 109 mg
(0.49 mmol, 66%) of 5-(4-fluorophenyI)-4H-pyrrolo[2,3-d]-1,3-thiazole as white
crystals; m.p. 244-245;
1H NMR (300 MHz, DMSO-d6): 6 [Ppm] 6.87 (d, Ji-tH = 2.0 Hz, 1H), 7.20-
7.29 (m, 2H), 7.75-7.83 (m, 2H), 8.77 (s, 1H), 12.33 (bs, 1H).
13C NMR (100 MHz, DMSO-d6): 6 [ppm] 96.58, 114.59, 115.75 (d, 2Jc,F =
19 Hz), 126.05 (d, 3,k,F = 7 Hz), 129.24, 135.17, 150.79, 152.97, 161.05
(d, 1Jc,F = 250 Hz);
ESI-MS: Rt: 2.28 min; m/e (%): 219 (100, [m+Fir).
35
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 76 -
Example 6
Preparation of 5-(4-fluoropheny1)-2-morpholin-4-y1-4H-pyrrolo[2,3-d]thia-
zole ("Al2")
0 _/ s
126 mg (0.50 mmol) of 2-chloro-5-(4-fluoropheny1)-4H-pyrrolo[2,3-d]thiazole
are suspended in 2 ml of morpholine in a microwave vessel and irradiated at
130 C for 2 h and subsequently purified directly by chromatography on silica
gel (eluent: cyclohexane/ethyl acetate 1/1), giving 139 mg (0.45 mmol, 91%)
of 5-(4-fluoropheny1)-2-morpholin-4-y1-4H-pyrrolo[2,3-dithiazole as beige
crystals; m.p. 240-248;
1H NMR (300 MHz, DMSO-d6): 5 [ppm] 3.35-3.51 (m, 4H), 3.66-3.81 (m,
4H), 6.65 (d, JFLH = 1.3 Hz, 1H), 7.16 (t, JH,H = 8.9 Hz, 2H), 7.55-7.69 (m,
2H), 11.78 (s, 1H);
13C NMR (75 MHz, DMSO-d6): 5 [ppm] 48.03, 65.34, 97.17, 105.45,
115.48 (d, 2Jc F = 21 Hz), 124.52 (d, 3Jc,F = 7 Hz), 128.77, 129.90, 148.59,
160.11 (d, 1Jc,F = 240 Hz), 170.62;
ESI-MS: Rt: 2.33 min; m/e (%): 304 (100, [m+Hr).
The following compounds are obtained analogously to the examples
described above
Compound m.p. VC];
Name and/or structure
No. MS
"A3" 150-151;
APCI-MS: Rt: 2.50
4H-Pyrrolo[2,3-d]thiazole
min; m/e (%): 125
(100, [M+H]+)
CA 02784067 2012-06-12
,
WO 2011/072779 PCTIEP2010/006822
- 77 -
1H NMR (300 MHz, DMSO-d6): 6 [ppm] 6.39 (dd, JH,H = 3.1 Hz, JH,H = 1.8
Hz, 1H), 7.12 (td, JH,H = 3.0 Hz, JH,H = 1.4 Hz, 1H), 8.73 (d, JH,H= 1.3 Hz,
1H), 11.79 (s, 1H);
13C NMR (75 MHz, DMSO-d6) 6 [ppm] 98.83, 112.86, 122.94, 150.39,
151.94.
"A4" 3-(4H-Pyrrolo[2,3-d]thiazol-5-yl)phenyl-
amine 160-161;
ESI-MS: Rt: 1.57
N N
min; m/e WO: 216
(100, [M+Hr)
NH2
NMR (300 MHz, DMSO-d6): 6 [ppm] 5.10 (s, 2H), 6.49 (d, JH,H = 7.5 Hz,
1H), 6.69 (d, JH,H = 1.6 Hz, 1H), 6.98-6.83 (m, 3H), 7.05 (t, JH,H = 8.0 Hz,
1H), 8.73 (s, 1H), 12.15 (s, 1H);
13C NMR (75 MHz, DMSO-d6) 6 [ppm] 95.82, 109.74, 112.33, 112.90,
114.34, 129.23, 133.16, 137.13, 148.78, 150.08, 152.66.
"A5" Benzy144-(4H-pyrrolo[2,3-cithiazol-5-y1)-
pyridin-2-yl]amine
z N ESI-MS: m/e (%):
H NH 307 (100, [M+H]+)
N
=
"A6" 169-170;
Benzy143-(4H-pyrrolo[2,3-clIthiazol-5-y1)-
ESI-MS: m/e (%):
phenyl]amine
306 (100, [M+H]+)
CA 02784067 2012-06-12
WO 2011/072779 PCT/EY2010/006822
- 78 -
H =NH
N
LL_
1H NMR (400 MHz, DMSO-d6): 6 [ppm] 4.34 (d, JH,H = 6.1 Hz, 2H), 6.27 (t,
= 6.1 Hz, 1H), 6.51 (dd, JH,H = 8.0 Hz, JH,H = 1.5 Hz, 1H), 6.71 (d, =
71..93 HFizz,, 11HH)),, 67..8383 -(t7, J.OH1,H(:7,.26HH),z 7, 2.0H7),(t7,
.J4H1ji(=d,7J.H8.HH:,71.6H)H,z7;222H)(,t,8 ,1.7H,4H
= 10
1H), 12.20 (s, 1H);
13C NMR (100 MHz, DMSO-d6): 6 [ppm] 45.83, 95.44, 107.06, 111.13,
111.73, 113.85, 126.07, 126.75, 127.72, 128.69, 132.61, 136.59, 139.79,
148.45, 149.75, 152.14.
"A2" 5-Benzy1-4H-pyrrolo[2,3-d]thiazole
m.p. 117-122;
ESI-MS: m/e: 215
([M-FH]+);
1H NMR (400 MHz, DMSO-d6): 6 [ppm] 3.99 (s, 2H), 6.13 (bs, 1H), 7.17-
7.32 (m, 5H), 8.62 (s, 1H), 11.78 (bs, 1H);
13C NMR (100 MHz, DMSO-d6): 6 [ppm] 33.86, 96.48, 112.32, 125.58,
127.80, 127.90, 136.04, 139.35, 148.15, 150.93;
APC1-MS: Rt: 3.97 min; m/e (%): 215 (100, [M+Fi])-
"A8" 6-Benzy1-2-pyridin-4-y1-4H-pyrrolo[2,3-d]-
thiazole
185-187=
,
ESI-MS: Rt: 1.89
N \
min; m/e (%): 292
N 1101
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 79 -
1H NMR (400 MHz, DMSO-d6): 6 [ppm] 3.94 (s, 2H), 7.08-7.39 (m, 6H),
7.75 (dd, JH,H = 4.5 Hz, JH,H = 1.6 Hz, 2H), 8.61 (dd, JH,H = 4.5 Hz, JH,H
1.6 Hz, 2H), 11.86 (s, 1H);
13C NMR (100 MHz, DMSO-d6): 6 [ppm] 31.87, 113.71, 114.42, 118.53,
122.03, 125.58, 127.91, 128.00, 139.68, 140.45, 150.01, 151.13, 159.15
"A9" 4-(4H-Pyrrolo[2,3-d]thiazol-5-yl)pyridin-2-
yNlamin(e_\
ESI-MS: Rt: 1.27
N___
min; m/e (%): 217
/71 (100,
[M+H])
NH,
1H NMR (500 MHz, DMSO-c16): 6 [PPrn] 6.05 (s, 2H), 6.51 (d, JH,H = 8.6 Hz,
1H), 6.66 (d, JH,H = 1.9 Hz, 1H), 7.75 (dd, JH,H = 8.6 Hz, JH,H = 2.4 Hz, 1H),
8.35 (d, JH,H = 2.2 Hz, 1H), 8.68 (d, JH,H = 3.5 Hz, 1H), 12.09 (s, 1H)
"A10" 150-151;
2-Chloro-5-(4-fluoropheny1)-4H-pyrrolo-
[2,3-d]thiazole ESI(-)-MS: Rt: 2.54
min; m/e (%): 250
(100, [M-2H]), 252
j/ F (45,
[Mf), 251 (20,
[M-1Hy)
1H NMR (300 MHz, DMSO-d6): 6 [ppm] 6.83 (s, 1H), 7.13-7.35 (m, 2H),
7.66-7.90 (m, 2H), 12.48 (s, 1H);
13C NMR (75 MHz, DMSO-d6): 6 [ppm] 97.24, 115.78 (d, 2Jc,F = 21 Hz),
126.15 (d, 3Jc,F = 7 Hz), 128.78, 134.37, 145.89, 147.25, 150.15, 161.17 (d,
1 Jc,F = 243 Hz)
"All" >200;
5-(4-Fluorophenyl)-2-(4-fluoropheny1- ESI-MS:
Rt: 2.91
ethyny1)-4H-pyrrolo[2,3-d]thiazole min; m/e
(%): 337
(100, [M+H])
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 80 -
/ -F
1H NMR (400 MHz, DMSO-d6): 6 [ppm] 6.92 (s, 1H), 7.25-7.36 (m, 4H),
7.68-7.76 (m, 2H), 7.84 (dd, JH,H = 8.8 Hz, JH,H 5.4 Hz, 2H), 12.55 (s, 1H)
"A13" 5-(4-Fluoropheny1)-2-(4-pyridin-4-ylmethyl-
piperazin-1-yI)-4H-pyrrolo[2,3-d]thiazole >170;
ESI-MS: Rt: 1.88
S
1H NMR (400 MHz, DMSO-d6): 6 [ppm] 2.52-2.56 (m, 4H), 3.42-3.49 (m,
5H), 3.59 (s, 2H), 6.65 (d, JH,H = 1.9 Hz, 1H), 7.16 (t, JH,H= 8.9, 2H), 7.37
(d, JH,H= 5.6 Hz, 2H), 7.62 (dd, JH,H = 8.8 Hz, JH,H = 5.4 Hz, 2H), 8.53 (d,
JH,H= 5.3 Hz, 2H), 11.77 (s, 1H);
13C NMR (100 MHz, DMSO-d6): 6 [ppm] 47.37, 51.16, 59.87, 96.69, 105.00,
115.00 (d, 2Jc,F = 22 Hz), 120.53, 123.24, 123.94 (d, 3,/c,F = 8 Hz), 128.08,
129.41, 147.64 (d, 1Jc,F = 220 Hz), 148.20, 149.06, 169.79
"A14" 5-[5-(4-FluorophenyI)-4H-pyrrolo[2,3-d]-
>220;
thiazol-2-yl]pyrimidin-2-ylamine
ESI-MS: Rt: 2.20 min
H
" N = F m/e
CYO: 312 (100,
N¨ [M+Hr)
S
1H NMR (400 MHz, DMSO-d6): 6 [ppm] 6.89 (d, JH,H = 1.9 Hz, 1H), 7.20 (s,
2H), 7.21 ¨7.30 (m, 4H), 8.74 (s, 2H), 12.37 (s, 1H)
"A16" 121-122;
tert-Butyl [5-(3-phenylprop-1-ynyl)thiazol-
ESI-MS: m/e CYO:
4-yl]carbamate
259 (100, [M-
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 81 -
tBu+2H]+), 314 (68,
[M]+), 315 (10,
// = [M+H]+)
1H NMR (300 MHz, DMSO-d6): 6 [ppm] 1.41 (s, 9H), 3.93 (s, 2H), 7.15 ¨
7.45 (m, 5H), 8.88 (s, 1H), 9.33 (s, 1H);
13C NMR (75 MHz, DMSO-d6): 6 [ppm] 25.15, 27.94, 71.64, 79.12, 97.52,
126.59, 127.84, 128.43, 136.01, 150.46, 2x 151.35, 152.64
"A17" tert-Butyl (5-triethylsilanylethynylthiazol- 88-90;
4-yl)carbamate APCI-MS:
Rt: 5.52
min; m/e (%): 282
(100, [M-tBu+2H]),
O 239 (40, [M-
B0C+H]+), 338 (17,
[M])
1H NMR (300 MHz, DMSO-d6): ö [ppm] 0.62 (dt, JH,H = 8.3 Hz, JE0 = 4.2
Hz, 6H), 0.98 (t, JH,H = 7.8 Hz, 9H), 1.43 (s, 9H), 8.91 (s, 1H), 9.39 (s,
1H);
13C NMR (75 MHz, DMSO-d6): 6 [ppm] 3.71, 7.28, 27.91, 79.17, 94.95,
101.41, 107.65, 151.40, 152.28, 152.37
"A18" tert-Butyl [5-(3-aminophenylethyny1)-
thiazol-4-Acarbamate
166-167;
ESI-MS: Rt: 1.99
min; m/e (YO): 316
0 NH
(100, [M+H])
N N NH2
1F1 NMR (400 MHz, DMSO-d6): 6 [ppm] 1.45 (s, 9H), 5.27 (s, 2H), 6.57 ¨
6.71 (m, 3H), 7.05 (t, Ji-th= 7.8 Hz, 1H), 8.95 (s, 1H), 9.50 (s, 1H).
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 82 -
El-MS: m/e (%): 215 (100, [M-BOC]), 315 (20, [M]);
130 NMR (100 MHz, DMSO-d6): 6 [ppm] 27.45, 77.09, 78/9, 98.37, 106.73,
114.36, 115.24, 117.99, 121.57, 128.68, 148.30, 150.13, 151.64, 151.95
"A19" tert-Butyl [5-(3-benzylaminophenyl-
ethynyl)thiazol-4-yl]carbamate 126-129;
ES1-MS: Rt: 2.61
7/'0min; m/e (%): 250
4111 1,1 (100, [M-tBu+2H]),
1101
406 (20, [M+H])
1H NMR (400 MHz, DMSO-d6): 6 [ppm] 1.43 (s, 9H), 4.28 (d, JH,H= 6.0 Hz,
2H), 6.47 (t, JF-1,1-1= 6.1 Hz, 1H), 6.61 ¨ 6.70 (m, 3H), 7.04 ¨ 7.13 (m, 1H),
7.18 ¨ 7.31 (m, 1H), 7.31 ¨ 7.45 (m, 4H), 8.94 (s, 1H), 9.49 (s, 1H);
13C NMR (100 MHz, DMSO-d6): 6 [ppm] 27.44, 45.61, 77.28, 78.77, 98.37,
106.61, 113.10, 113.23, 118.24, 121.67, 126.17, 126.54, 127.80, 128.67,
139.24, 148.18, 150.16, 151.70, 151.91
"A20" tert-Butyl [5-(2-benzylaminopyridin-4-yl- 185-189;
ethynyl)thiazol-4-yl]carbamate El-MS: m/e (%): 57
(65, [CCH3r.), 105
/ N
00, [ C7H7N]), 306
N
(55, [M-
/i
OCOCCH3r.), 406
(40, [M])
1H NMR (400 MHz, DMSO-d6): 6 [ppm] 1.44 (s, 9H), 4.48 (d, JKH = 6.0 Hz,
2H), 6.49 ¨ 6.59 (m, 2H), 7.20 ¨ 7.29 (m, 2H), 7.31 (d, JRH = 4.4 Hz, 4H),
7.98 (d, JH,H = 5.2 Hz, 1H), 9.01 (s, 1H), 9.68 (s, 1H);
13C NMR (100 MHz, DMSO-d6): 6 [ppm] 27.43, 43.50, 78.97, 80.87, 95.75,
104.86, 108.56, 112.22, 126.05, 126.59, 127.70, 129.54, 139.70, 147.59,
151.21, 151.73, 152.89, 158.15
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 83 -
"A21" tert-Butyl [5-(1H-pyrrolo[2,3-b]pyridin-5-yl-
ethynyl)thiazol-4-yllcarbamate
>158 (decomposition);
N N
ESI-MS: Rt: 2.04
NH 5 / min; m/e
(%): 341
o (100, [M+H]+)
1\1,
1H NMR (300 MHz, DMSO-d6): 6 [PPm] 1.47 (s, 9H), 6.50 (d, JHH= 3.4 Hz,
1H), 7.41 ¨ 7.67 (m, 2H), 8.11 (d, JH,H -= 2.0 Hz, 1H), 8.34 (d, JH,H = 1.9
Hz,
1H), 8.96 (s, 1H), 9.54 (s, 1H), 11.93 (s, 1H);
13C NMR (75 MHz, DMSO-d6): 6 [ppm] 27.95, 79.30, 97.06, 100.28, 106.89,
110.16, 119.11, 127.66, 130.63, 144.87, 146.02, 147.54, 150.75, 152.10,
152.43
"A22" 5-(1H-Pyrrolo[2,3-b]pyridin-5-ylethyny1)-
thiazol-4-ylamine
NH ESI-MS:
m/e (c)/0):
2
241 (100, [M+H]+)
N \
"A23" 192-193;
tert-Butyl (2-pyridin-4-ylthiazol-4-y1)-
El-MS: m/e (%): 57
carbamate
(100, [CCH3]), 177
N (80, [M-BOCr), 277
(10, [M]').
s? ESI-MS: m/e (%):
278 (100, [M+H] )
1F1 NMR (300 MHz, DMSO-d6): 6 [ppm] 1.49 (s, 9H), 7.45 (s, 1H), 7.81 (dd,
= 4.5 Hz, JH,H = 1.6 Hz, 2H), 8.70 (dd, JH,H = 4.5 Hz, JH,H = 1.6 Hz, 2H),
10.38 (s, 1H);
130 NMR (75 MHz, DMSO-d6): 6 [ppm] 27.98, 79.64, 101.56, 119.47,
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 84 -
139.30, 149.91, 150.68, 152.76, 161.16
"A24" tert-Butyl N-(2-pyridin-4-y1-5-iodo-1,3-
thiazol-4-Acarbamate 197;
El-MS: m/e (%): 57
N
0 7. (100, [CCH3]4.), 303
0
(80, [M-BOC]), 403
(10, [M])
1H NMR (400 MHz, DMSO-d6): 6 [IDPrn] 1.46 (s, 9H), 7.80 (dd, JH,F4 = 4.5
Hz, JH,H = 1.6 Hz, 2H), 8.72 (dd, JH = 5.9 Hz, JH = 1.5 Hz, 2H), 9.27 (s,
1H);
13C NMR (100 MHz, DMSO-d6): 6 [ppm] 27.52, 73.10, 78.88, 118.88,
138.16, 150.32, 152.32, 165.41
"A25" tert-Butyl [5-(3-morpholin-4-ylprop-1-yny1)-
2-pyridin-4-ylthiazol-4-yllcarbamate
94-100;
0 ESI-MS: Rt: 1.37
min; m/e (%): 401
NH
IIS
(100, [M+H]+)
/ \
N
"A26" 132-141;
-
tert-Butyl {543-(1,3-dioxo-1,3-dihydro- ESI-MS: Rt: 2.19
isoindo1-2-yl)prop-1-ynyllthiazol-4-yll- min; m/e (%): 328
carbamate (100, [M-tBu+2H]+),
384 (15, [M+Hl+)
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 85 -
0
O
N
=5 0
-1H NMR (400 MHz, DMSO-d6): 6 [ppm] 1.33 (s, 9H), 4.65 (s, 2H), 7.84 -
7.96 (m, 4H), 8.91 (s, 1H), 9.44 (s, 1H);
130 NMR (100 MHz, DMSO-d6): 6 [ppm] 27.16, 27.29, 71.37, 78.69, 92.47,
105.53, 122.81, 130.95, 134.18, 150.82, 151.78, 151.97, 166.11
"A27" 3-(4-Aminothiazol-5-ylethynyl)phenol
ESI-MS: Rt: 1.83
NH2 OH
min; m/e (%): 217
N\
5 _____
(100, [M+H]+)
"A28" tert-Butyl [2-(2-aminopyridin-3-yI)-5-(4-
fluorophenylethynyl)thiazol-4-yl]carbamate
0 F ESI-MS: Rt: 3.32
I\114
0¨\ min; m/e
(%): 411
N
(100, [M+H]+)
'N7NH2
1H NMR (400 MHz, DMSO-d6): 6 [ppm] 1.48 (s, 9H), 6.67 (dd, JH,H= 7.7
Hz, JH,H -= 4.7 Hz, 1H), 7.35 - 7.25 (m, 2H), 7.58 - 7.67 (m, 4H), 7.90 (dd, J
= 7.7 Hz, JH,H = 1.7 Hz, 1H), 8.13 (dd, JH,H = 4.7 Hz, JH,H = 1.7 Hz, 1H),
9.89
(s, 1H);
13C NMR (100 MHz, DMSO-c16): 6 [PPrn] 27.43, 78.41, 79.32, 97.25, 100.85,;
108.17, 111.68, 115.55 (d, 2Jc,F = 23 Hz), 118.02, 132.90 (d, 3Jc,F = 8 Hz),
135.56, 149.33, 150.59, 151.41, 155.11, 161.62 (d, 1Jc,F = 247 Hz), 162.98
"A30" 345-(4-Fluoropheny1)-4H-pyrrolo[2,3-d]- 300-301;
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 86 -
thiazol-2-yllpyridin-2-ylamine ESI-MS:
R: 1.95
min; m/e (%): 311
N
cF (100, [M+H])
S
NH2
"A31" >230 (decomposition)
315-(4-Fluoropheny1)-4H-pyrrolo[2,3-d]-
thiazol-2-y1]-5-(1-piperidin-4-y1-1H-pyrazol-
ESI-MS: R. 1.70 min;
$ m/e (Y0): 460 (100,
4-yl)pyridin-2-ylamine
[M+Fi]+);
1-4 F Esi-HRMS: R: 4.55
/
HNjjj-N min, m/e [M+H]" ;
CIH
calculated for
N NH2 C24H23FN7S: 460.1719;
CIH
found: 460.1704
NMR (400 MHz, DMSO-d6): 6 [ppm] 2.30-2.13 (m, 4H), 3.17-3.08 (m,
2H), 3.45-3.40 (m, 2H), 4.57-4.50 (m, 1H), 7.02 (d, J = 1.7 Hz, 1H), 7.32
(d, J = 8.9 Hz, 2H),7.86 (d, J = 3.4 Hz, 2H), 8.06 (s, 1H), 8.33 (s, 1H), 8.39
(d, J= 1.9 Hz, 1H), 8.41 (s, 1H), 12.58 (s, 1H);
13C NMR (100 MHz, DMSO-d6): 6 [ppm] = 28.03, 41.33, 54.87, 94.87,
96.83, 115.3 (d, 2Jc,F = 22 Hz), 115.86, 115.98, 117.9, 125.6, 125.9 (d,
3JC,F = 7 Hz), 128.0, 135.8, 135.6, 136.5, 148.6, 150.9, 157.9, 159.6, 160.9
(d, 1Jc,F = 250 Hz)
"A32" 116-118;
6-(4,4-Dimethylpent-2-ynyI)-4H-pyrrolo- ESI-MS: Rt: 2.40 min;
[2,3-dlthiazole $ rn/e (%): 219 (100,
HN ESI-HRMS: Rt: 6.19
min, m/e [M+H]; rn/e
N/S calculated for
C12H15N2S: 219.0956;
found: 219.0951
NMR (300 MHz, DMSO-d6): 6 [ppm] = 1.21 (d, J = 8.6 Hz, 9H), 2.51
CA 02784067 2012-06-12
,
WO 2011/072779
PCT/EP2010/006822
- 87 -
(dd, J= 3.6 Hz, 1.8 Hz, 1H), 3.52 (d, J= 0.7 Hz, 2H), ), 6.94 (dd, J= 2.3
Hz, 1.2 Hz, 1H), 8.72 (d, J = 1.3 Hz, 1H), 11.58 (s, 1H);
13C NMR (75 MHz, DMSO-d6): 6 [PPml = 16.27, 26.99, 31.03, 76.00,
89.60, 109.98, 112.08, 119.57, 150.62, 151.57
"A33" >167
Methyl 2-tert-butyl-3-(4H-pyrrolo[2,3-d]-
(decomposition);
thiazol-6-ylmethyl)-1H-indole-5-
ESI-MS: Rt: 2.42 min;
carnoxylate
$ m/e CYO: 368 (100,
[M+ H]4);
ESI-HRMS: Rt: 6.08
min, m/e [M+Flr; m/e
0 calculated for
N C201-122N302S:
368.1432; found:
368.1425
1H NMR (300 MHz, DMSO-d6): 6 [ppm] = 1.46 (s, 9H), 3.83 (s, 3H), 4.27
(s, 2H), 6.93 (d, J = 1.0 Hz, 2H), 7.45 (d, J = 8.5 Hz, 1H), 7.72 (dd, J = 8.5
Hz, J = 1.6, 1H), 8.07 (d, J = 1.4 Hz, 1H), 8.54 (d, J= 1.3 Hz, 1H), 11.01 (s,
1H), 11.53 (s, 2H);
13C NMR (75 MHz, DMSO-d6): 6 [ppm] = 21.72, 30.39, 33.26, 51.41,
107.98, 110.48, 114.55, 119.34, 119.44, 120.26, 120.79, 121.46, 121.62,
125.43, 129.12, 137.42, 144.72, 150.12
"A34" 2-tert-Butyl-3-(4H-pyrrolo[2,3-d]thiazol-6- 220-225;
ylmethyl)-1H-pyrrolo[2,3-b]pyridine ESI-MS: Rt: 1.77 min;
$
N m/e (%): 311 (100,
, [M+Flr");
N \ I El-HRMS: m/e
NH
calculated for
C17H18N4S: 310.1252;
found: 310.1201
1H NMR (300 MHz, DMSO-d6): 6 [ppm] = 1.41 (s, 9H),
CA 02784067 2012-06-12
=
WO 2011/072779 PCT/EP2010/006822
- 88 -
4.16 (s, 2H), 6.97 ¨ 6.84 (m, 2H),7.67 (dd, J = 7.8 Hz, J= 1.2 Hz, 1H),
8.10 (s, 1H), 8.50 (d, J = 1.3 Hz, 1H), 11.10 (s, 1H), 11.46 (s, 1H);
13C NMR (75 MHz, DMSO-d6):15 [ppm] = 21.79, 30.44, 33.55, 39.53,
105.35, 112.15, 114.57, 114.66, 119.39, 121.73, 125.50, 141.45, 143.57,
147.63, 150.03, 151.37
"A35" 6-(3,5-DifluorobenzyI)-4H-pyrrolo-
F [20,3-d]thiazole
ESI-MS: R: 4.49 min;
N 5 [M]251
S z N
1H NMR (400 MHz, CDCI3) 6 [ppm] 8.61 (br. s, 1H), 8.48 (d, J = 1.3, 1H),
6.89(d, J = 1.0, 1H), 6.83 ¨ 6.74 (m, 2H), 6.67 (m, 1H), 3.96 (s, 2H)
"A36" 6-(4-MethoxybenzyI)-4H-pyrrolo-
[2,3-d]thiazole
ESI-MS: Rt: 4.123 min;
N [M]+ 245
S N
1H NMR (400 MHz, CDCI3) 6 [ppm] 8.66 (br. s, 1H), 8.50 (s, 1H), 7.19 (d, J
= 8.5, 2H), 6.87 (d, J = 8.5, 2H), 3.91 (s, 2H), 3.81 (s, 3H)
"A37" 6-(4-Bromobenzy1)-4H-pyrrolo[2,3-4
thiazole
ESI-MS: Rt: 4.793 min;
V N 5 [M]293
S N
Br
1H NMR (400 MHz, CDCI3) 6 [ppm] 8.61 (br. s, 1H), 8.47 (s, 1H), 7.46 ¨
7.41 (m, 2H), 7.15 (d, J = 8.4, 2H), 6.86 (s, 1H), 3.94 (s, 2H)
"A38" 6-(4-lsopropylbenzy1)-4H-pyrrolo- ESI-MS: Rt: 5.225 min;
CA 02784067 2012-06-12
WO 2011/0'72779 PCT/EP2010/006822
- 89 -
[2,3-d]thiazole __ [M] 257
410
1H NMR (400 MHz, CDCI3) 6 [ppm] 9.10 (br. s, 1H), 8.52 (d, J= 1.2, 1H),
7.27 (s, 5H), 7.19 (s, 4H), 6.90 (d, J= 1.0, 1H), 3.95 (s, 2H), 2.90 (quint,
J=
6.9, 1H), 1.25 (d, J = 6.9, 6H)
"A39" 6-(4-Bromo-2-fluorobenzy1)-4H-pyrrolo-
[2,3-d]thiazole
ESI-MS: Rt: 4.837 min;
N [M]311
S N
Br
1H NMR (400 MHz, CDCI3) 6 [ppm] 8.56 (br. s, 1H), 8.47 (d, J= 1.3, 1H),
7.24 (t, J = 8.8, 2H), 7.11 (t, J = 7.9, 1H), 6.88 (s, 1H), 3.96 (s, 2H)
"A40" 6-(4-tert-ButylbenzyI)-4H-pyrrolo-
[2,3-d]thiazole
4110 ESI-MS: Rt: 5.439 min;
5 [M] 271.3
I H NMR (400 MHz, CDCI3) 6 [ppm] 8.59 (br. s, 1H), 8.46 (s, 1H), 7.39 ¨
7.31 (m, 2H), 7.21 (d, J = 8.3, 2H), 6.85 (d, J = 1.1, 1H), 3.95 (s, 2H), 1.32
(s, 9H)
"A41" 6-(2-ChlorobenzyI)-4H-pyrrolo- ESI-MS: Rt: 4.581 min;
[2,3-d]thiazole 5 [M] 249
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 90 -
Cl
N
S N
1H NMR (400 MHz, CDC13) 6 [ppm] 9.11 (br. s, 1H), 8.51 (s, 1H), 7.40 (dd, J
= 7.3, 2.0, 1H), 7.29 (dd, J = 7.3, 2.3, 1H), 7.25 ¨ 7.21 (m, 1H), 7.21 ¨ 7.17
(m, 1H), 6.92 (d, J = 1.1, 1H),4.11 (s, 2H)
"A42" 6-(4-Fluorobenzy1)-4H-pyrrolo[2,3-d]- I
thiazole
ESI-MS: Rt: 4.37 min;
N
5 [M]+ 233
1110 S N
1H NMR (400 MHz, CDC13) 6 [ppm] 8.65 (br. s, 1H), 8.46 (s, 1H), 7.25 ¨
7.20 (m, 2H), 7.04 ¨ 6.96 (m, 2H), 6.85 (d, J= 1.0, 1H), 3.96 (s, 2H)
"A43" 6-(3-Fluorobenzy1)-4H-pyrrolo-
[2,3-d]thiazole
ESI-MS: Rt: 4.367 min;
= N
5 [M]- 233
S z N
1H NMR (400 MHz, CDC13) 6 [ppm] 8.80 (br. s, 1H), 8.49 (s, 1H), 7.29 (dd, J
= 7.0, 5.2, 1H), 7.06 (d, J = 7.5, 1H), 6.99 ¨ 6.90 (m, 2H), 6.89 (d, J = 1.0,
1H), 3.98 (s, 2H)
"A44" ESI-MS: RT:4.454
6-(2,3-Difluorobenzy1)-4H-pyrrolo-
min; [M] 251
[2,3-d]thiazole
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 91 -
r¨s
N
1
11101
1H NMR (400 MHz, CDCI3) [ppm] 8.95 (s, 1H), 8.51 (s, 1H), 7.04 (m, 3H),
6.93 (s, 1H), 4.04 (s, 2H)
"A45" 6-(2,4-DifluorobenzyI)-4H-pyrrolo-
[2,3-d]thiazole
F ES1-MS: RT: 4.488
min; 5 [M] 251
\
N N
1H NMR (400 MHz, CDCI3) 5 [ppm] 8.92 (s, 1H), 8.49 (s, 1H), 7.24 ¨ 7.16
(m, 1H), 6.87 (m, 1H), 6.82 (m, 1H), 3.96 (s, 2H)
"A46" 6-(2,5-Difluorobenzy1)-4H-pyrrolo-
[2,3-d]thiazole
ESI-MS: RT: 4.438
min; 5 [M]+ 251
N N
NMR (400 MHz, CDCI3) 6 [ppm] 9.54 (s, 1H), 8.63 (s, 1H), 7.07 ¨ 7.00
(m, 1H), 6.99 (s, 1H), 6.95 ¨ 6.88 (m, 2H), 3.99 (s, 2H)
"A47" 6-(3,4-Difluorobenzy1)-4H-pyrrolo- ESI-MS: RT:4.508 min;
[2,3-d]thiazole [MI+ 251
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 92 -46.
N N
H NMR (400 MHz, CDCI3) 6 [ppm] 8.93 (s, 1H), 8.52 (s, 1H), 7.13 - 7.06
(m, 1H), 7.07 -7.02 (m, 1H), 6.99 (s, 1H), 6.91 (s, 1H), 3.95 (s, 2H)
"A48" 6-(6-Chloropyridin-3-ylmethyl)-4H-pyrrolo-
[2,3-d]thiazole
CI ESI-MS: RT: 3.549
\ min; {mr 250
\
1H NMR (400 MHz, CDCI3) 6 [ppm] 9.17 (s, 1H), 8.55 (s, 1H), 8.36 (d, J=
2.3, 1H), 7.55 (dd, J- 8.2, 2.5, 1H), 7.29 (d, J = 8.4, 1H), 6.92 (s, 1H),
3.99
(s, 2H)
"A49" 6-(3-ChlorobenzyI)-4H-pyrrolo-
[2,3-d]thiazole
r-S ES1-MS: RT: 4.679
N le CI min; 5 [M]r 249
1H NMR (400 MHz, CDCI3) 6 [ppm] 8.56 (br. s, 1H), 8.46 (d, J= 1.4, 1H),
7.27 - 7.25 (m, 1H), 7.23 (m, 2H), 7.17 (m, 1H), 6.87 (m, 1H), 3.96 (s, 2H)
"A50" 6-(3,4-DichlorobenzyI)-4H-pyrrolo- ESI-MS: RT: 5.029
[2,3-d]thiazole min; 5 [M]` 283
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 93 -
______________________ r-S
$ CI
N
CI
1H NMR (400 MHz, CDCI3) 6 [ppm] 9.06 (br. s, 1H), 8.52 (s, 1H), 7.37 (dd, J
= 10.3, 5.1, 2H), 7.11 (dd, J- 8.2, 2.0, 1H), 6.89 (s, 1H), 3.94 (s, 2H)
6-benzy1-2-pyridin-3-y1-4H-pyrrolo[2,3-d]thiazole (''A51")
'H NMR (400 MHz, DMSO-d6) 6 [ppm] 11.77 (s, 1H), 9.02 (d, J = 2.2, 1H),
8.55 (dd, J = 4.8, 1.5, 1H), 8.20 - 8.09 (m, 1H), 7.46 (dd, J = 8.0, 4.8, 1H),
7.31 (m, 1H), 7.27 (m, 3H), 7.20(m, 1H), 7.09 (d, J= 2.4, 1H), 3.92 (s,
2H);
6-benzy1-2-(1-methy1-1H-pyrazol-4-y1)-4H-pyrrolo[2,3-d]thiazole ("A52")
1H NMR (400 MHz, DMSO-d6) 6 [ppm] 11.46 (s, 1H), 8.18 (s, 1H), 7.78 (d,
J= 0.7, 1H), 7.31 -7.22 (m, 4H), 7.21 -7.15 (m, 1H), 6.90 (d, J= 2.4,
1H), 3.87 (s, 2H), 3.84 (s, 3H);
5-(6-benzy1-4H-pyrrolo[2,3-d]thiazol-2-yl)pyridin-2-ylamine ("A53")
1H NMR (400 MHz, DMSO-d6) 6 [ppm] 11.49 (d, J = 2.0, 1H), 8.37 (d, J =
2.2, 1H), 7.75 (dd, J = 8.7, 2.5, 1H), 7.28 (m, 4H), 7.18 (m, 1H), 6.91 (d, J
= 2.4, 1H), 6.47 (dd, J = 8.8, 0.4, 1H), 6.41 (s, 2H), 3.87 (s, 2H);
6-prop-2-yny1-4H-pyrrolo[2,3-d]thiazole ("A54")
1H NMR (400 MHz, CDCI3) 6 [ppm] 8.63 (s, 1H), 8.53 (d, J = 1.1, 1H), 6.98
(d, J = 1.2, 1H), 3.62 (d, J = 2.0, 3H), 2.19 (t, J = 2.6, 1H);
3-(6-benzy1-4H-pyrrolo[2,3-d]thiazol-2-yl)pyridin-2-ylamine ("A55"),
6-benzy1-2-(1H-pyrazol-4-y1)-4H-pyrrolo[2,3-d]thiazole ("A56"),
CA 02784067 2012-06-12
WO 2011/072779
PCT/E P2010/006822
- 94 -6-benzy1-2-(5-bromopyridin-3-y1)-4H-pyrrolo[2,3-d]thiazole (''A57"),
6-benzy1-2-pyrimidin-5-y1-4H-pyrrolo[2,3-d]thiazole ("A58"),
morpholin-4-y143-(4H-pyrrolo[2,3-d]thiazol-6-ylmethyl)-1H-indol-5-y1]-
methanone ("A59"),
N-(2-methoxyethyl)-3-(4H-pyrrolo[2,3-d]thiazol-6-ylmethyl)-1H-indole-5-
. 10 carboxamide ("A60"),
N-(4-fluorobenzy1)-3-(4H-pyrrolo[2,3-d]thiazol-6-ylmethyl)-1H-indole-5-
,
carboxamide ("A61"),
N-(2-aminoethyl)-244-(4H-pyrrolo[2,3-d]thiazol-6-ylmethyl)-1,2,3-triazol-
1-yllacetamide ("A62"),
1-piperazin-1-y1-2-[4-(4H-pyrrolo[2,3-d]thiazol-6-ylmethyl)-1,2,3-triazol-
1-yl]ethanone ("A63"),
N-(piperidin-4-y1)-244-(4H-pyrrolo[2,3-d]thiazol-6-ylmethyl)-1,2,3-triazol-
1-yl]acetamide ("A64"),
6-(1-pyridin-3-ylmethy1-1H-1,2,3-triazol-4-ylmethyl) 4H-pyrrolo[2,3-d]-
thiazole ("A65"),
1H NMR (400 MHz, CDC13) 6 [ppm] 8.61 (dd, J = 4.8, 1.5, 1H), 8.58 (d, J =
1.9, 2H), 8.47 (d, J = 1.3, 1H), 7.58 (d, J = 8.4, 1H), 7.31 (dd, J = 7.8,
4.8,
1H), 7.25 (s, 1H), 6.93 (d, J = 1.1, 1H), 5.53 (s, 2H), 4.11 (s, 2H);
6-(1-pyridin-4-ylmethy1-1H-1,2,3-triazol-4-ylmethyl) 4H-pyrrolo[2,3-d]-
thiazole ("A66")
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 95 -
1H NMR (400 MHz, CDCI3) 6 [ppm] 8.61 (dd, J = 4.4, 1.6, 3H), 8.48 (d, J =
1.3, 1H), 7.09 (dd, J = 4.5, 1.5, 2H), 6.96 (d, J= 1.1, 1H), 5.53 (s, 2H),
4.14 (s, 2H);
6-benzy1-2-(5-(1-methy1-1H-pyrazol-4-yhpyridin-3-y1)-4H-pyrrolo[2,3-d1-
thiazole ("A67"),
6-benzy1-2-(5-(1H-pyrazol-4-yhpyridin-3-y1)-4H-pyrrolo[2,3-d]thiazole
= 10 ("A68"),
6-benzy1-2-(5-(4-fluorophenyl)pyridin-3-y1)-4H-pyrrolo[2,3-d]thiazole
("A69"),
6-(5-methanesulfonylthiophen-2ylmethyl)-4H-pyrrolo[2,3-d]thiazole ("A70"),
6-[1-(2-morpholin-4-ylethyl)-1H-1,2,3-triazol-4-ylmethyl) 4H-pyrrolo[2,3-d]-
thiazole ("A71")
1H NMR (400 MHz, CDCI3) 6 [ppm] 8.57 (s, 1H), 8.49 (d, J= 1.3, 1H), 7.42
(s, 1H), 6.96 (d, J = 1.1, 1H), 4.43(t, J= 6.3, 2H), 4.12 (s, 2H), 3.71 -3.60
(m, 5H), 2.80 (t, J = 6.3, 2H), 2.53 - 2.42 (m, 4H);
6-benzy1-2-{5414(E)-3-phenylally1)-1H-pyrazol-4-yl]pyridin-3-y1}-4H-pyrrolo-
[2,3-d]thiazole ("A72")
1H NMR (400 MHz, DMSO-d6) 6 [ppm] 11.47 (s, 1H), 8.27 (s, 1H), 7.85 (d, J =
0.6, 1H), 7.45 (d, J = 7.1, 2H), 7.36 - 7.22 (m, 7H), 7.21 - 7.15 (m, 1H),
6.91
(d, J = 2.4, 1H), 6.59 (d, J- 16.0, 1H), 6.51 (t, J= 6.1, 1H), 4.92 (d, J=
5.9,
2H), 3.87 (s, 2H).
Results of the receptor binding tests
The compounds shown here were tested at a concentration of 1 pM
CA 02784067 2012-06-12
WO 2011/072779
PCT/EP2010/006822
- 96 -
against 102 kinases, As shown by the comparison, both the compounds of
the formula la and also those of the formula lb are associated with a high
degree of potency and selectivity, making them suitable for use in targeted
tumour therapy.
The % values indicated are a measure of the residual kinase activity
remaining if the kinase is treated with the substance under the conditions
described in the filter binding assay. Within the bounds of measurement
accuracy, it can be assumed that a % value of about 50 corresponds to an
= 10 IC50 of 11.1M. M.W. Karaman et al. in Nature Biotechnology
2008; 26 (1):
127 - 32, describe the quantitative analysis of kinase inhibitor selectivity.
Some compounds according to the invention are shown by way of example
below along with the kinases which inhibits the substance to the extent of
about 50% or greater:
= 6-benzy1-4H-pyrrolo[2,3-d]thiazole ("A7")
Aurora A (33%); Rock II (36%); CDK2 (41%); CK2 (53%); NUAK1
(27%);
= 3-(4-aminothiazol-5-ylethynyl)phenol ("A27")
Nek2A (59%); NUAK1 (49%);
= tert-butyl {543-(1,3-dioxo-1,3-dihydroisoindo1-2-ypprop-1-ynyli-
thiazol-4-y1}carbamate ("A26")
CDK2 (28%); NUAK1 (24%);
= tert-butyl [543-morpholin-4-ylprop-1-yny1)-2-pyridin-4-ylthiazol-4-y1]-
carbamate ("A25")
HIPK1 (48%);
= 5-(1H-pyrrolo[2,3-b]pyridin-5-ylethynyl)thiazol-4-ylamine ("A22")
Aurora A (39%); HIPK1 (36%); MARK2 (31%); MKK1 (43%); PDK1
(53%); GSK3b (9%); CHK1 (40%); CDK2 (52%); PRK2 (38%); MAPK8
(34%); MARK3 (15%); HIPK2 (44%); PAK4 (34%); VEGFR (11%); GCK
31%); NUAK1 (16%); MLK3 (23%).
CA 02784067 2012-06-12
, .
WO 2011/072779 PCT/EP2010/006822
- 97 -
If it is furthermore assumed that the kinase inhibitors behave normally in
the activity measurement concentration range considered, a regression
line having a slope of 1 can be assumed for this range considered. IC50
values shown below for the compounds can thus be obtained for a multi-
plicity of kinases.
IC50: 10 nM ¨ 1 M = A; 1 [iM - 10 !AM = B; 10 p.M - 100 M =
C
NA here means that the compound has exerted absolutely no inhibitory
effects on the kinase (no activity) at the test concentration of 1 pM.
It can be seen from the table with the IC50 values derived from the %
inhibition
data that the compounds presented here provide an extremely high measure
,
of flexible kinase inhibition.
Kinase "A26" "A7" "A27" "A22" "A25" "A31"
MAP2K1 B B NA A B
SRC C B B C B
MAPK1 ' C NA B C NA '
MAPK8 C B B r B NA
MAPK14 C B B C C
MAPK11 NA B B NA NA
MAPK12 C NA B B C
MAPK13 C B B C NA
RPS6KA1 NA C NA NA C
MAPKAPK2 C NA C NA NA
RPS6KA5 NA B C C C
MAPKAPK5 B NA C C NA
PRKCA B C NA B C
PDPK1 B NA NA B NA r
AKT1 NA NA NA ' C NA
SGK B NA NA B C
RPS6KB1 NA B B B NA
GSK3B B B B A NA
ROCK2 NA A C NA C
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 98 -
PRKAA1 C C B C C
CH EK1 C NA C A C
CSNK2A1 C NA NA NA NA
CS K C B C C NA
CDK2 A A C B C
CSNK1D NA B B C NA
NEK6 C C C NA B
NEK2 B NA B NA B
LCK NA C B NA NA
- PRKACA C NA B B NA
PBK C NA NA B NA
' RPS6KA3 NA B B C NA
IKBKB NA B B C NA
MYLK NA NA B NA NA
PKN2 B B C A NA
MKNK2 C NA NA NA NA
CAM K1 NA B B C B
PIM2 NA NA B C B
MAPK10 NA NA B NA NA
MAPKAPK3 NA NA C NA C
__________________________________________________________________________ 11
MAPK8 B NA NA A NA
MKNK1 NA NA C C NA
SRPK1 NA C B NA NA
AKT2 NA NA B NA B
AURKB NA B C C NA
CHEK2 NA NA C NA NA
EEF2K C C B C NA
II
MARK3 B B C A NA
STK3 NA B B C NA
PRKD2 NA B B NA NA
MAPK9 NA C B NA NA
DYRK3 B C C C C
H IPK2 B , NA NA A NA
CA 02784067 2012-06-12
WO 2011/072779 PCT/EP2010/006822
- 99 -
HIPK3 C B B B C
PAK4 B NA NA A NA
DYRK2 NA NA B NA NA
,
CAM KK2 C C C NA NA
PIM1 C C B B NA
PIM3 NA B B C NA
PAK6 NA NA C C C
PLK1 NA NA C B NA
BRSK2 NA NA C NA NA
MELK NA B B NA NA
PRKCZ C NA NA NA C
MAPK1 C C NA B C
FGFR1 B B NA B NA
INSRR B NA NA B NA 11
EPHA2 NA C NA NA NA
MST4 C NA NA B NA
SYK NA NA C C NA
YES1 NA NA NA B NA
IGF1R NA C NA B NA
KDR NA B B A NA
BTK NA C C C C
INSR B NA C C NA
EPHB3 B NA B C NA
TBK1 NA NA NA NA C A
IKBKE C C NA NA B
NUAK1 A A A A = C
MAP3K9 B B B B NA
MINK1 C B B B C
MAP4K2 B B B A NA
I RAK4 C NA C NA C
TTK C C C C C
DYRK1A C NA C NA NA
MAP3K11 B C C A NA
CA 02784067 2012-06-12
,
'
WO 2011/072779 PCT/EP2010/006822
- 100 -
STK11 C C NA NA NA
1 ERBB4 NA C B NA NA
PAK2 NA B NA NA NA
BRSK1 NA B B B NA
AURKA B A B A NA
________________________________________________________________________ -
RIPK2 C C B B NA
HIPK1 NA NA B A A
MARK4 NA ' NA B C C
MARK2 B C C A NA
MET NA B C NA NA
TGFBR1 C C B C B
= PDPK1 C NA NA B NA
The following examples relate to medicaments:
Example A: Injection vials
A solution of 100 g of an active ingredient of the formula l and 5 g of
disodium hydrogenphosphate in 3 l of bidistilled water is adjusted to pH 6.5
using 2 N hydrochloric acid, sterile filtered, transferred into injection
vials,
lyophilised under sterile conditions and sealed under sterile conditions.
Each injection vial contains 5 mg of active ingredient.
Example B: Suppositories
A mixture of 20 g of an active ingredient of the formula l with 100 g of soya
lecithin and 1400 g of cocoa butter is melted, poured into moulds and
allowed to cool. Each suppository contains 20 mg of active ingredient.
Example C: Solution
A solution is prepared from 1 g of an active ingredient of the formula l,
9.38 g of NaH2PO4 - 2 H20, 28.48 g of Na2HPO4 - 12 H20 and 0.1 g of
benzalkonium chloride in 940 ml of bidistilled water. The pH is adjusted to
81565053
- 101 -
6.8, and the solution is made up to 1 l and sterilised by irradiation. This
solution can be used in the form of eye drops.
Example D: Ointment
500 mg of an active ingredient of the formula l are mixed with 99.5 g of
VaselinTMe under aseptic conditions.
Example E: Tablets
A mixture of 1 kg of active ingredient of the formula l, 4 kg of lactose,
1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is
pressed in a conventional manner to give tablets in such a way that each
tablet contains 10 mg of active ingredient.
Example F: Dragees
Tablets are pressed analogously to Example E and subsequently coated in
a conventional manner with a coating of sucrose, potato starch, talc, traga-
canth and dye.
Example G: Capsules
2 kg of active ingredient of the formula I are introduced into hard gelatine
capsules in a conventional manner in such a way that each capsule con-
tains 20 mg of the active ingredient.
Example H: Ampoules
A solution of 1 kg of active ingredient of the formula I in 60 l of
bidistilled
water is sterile filtered, transferred into ampoules, lyophilised under
sterile
conditions and sealed under sterile conditions. Each ampoule contains
10 mg of active ingredient.
CA 2784067 2017-08-03
